“双固一通”针法对绝经后骨质疏松症模型大鼠OPG/RANKL/RANK系统的调节
|
摘要
目的
观察“双固一通”针法对去卵巢绝经后骨质疏松症(postmenopausal osteoporosis, PMO)模型大鼠调节骨吸收平衡的相关细胞因子系统——护骨素(osteoprotegerin, OPG)/核因子κB受体活化因子配体(receptor activator of nuclear factor-κB ligand,RANKL)/核因子κB受体活化因子(receptor activator of nuclear factor-κB, RANK)系统的影响,进一步探讨“双固一通”针法治疗本病的作用机制,为针灸治疗PMO提供新的思路和方法,为临床预防和治疗PMO提供实验依据。
方法
依随机原则将50只SD大鼠分为对照组、模型组、常规取穴针刺组(简称常规组)、“双固一通”针刺组(简称双固一通组)和中成药治疗组(简称中成药组),每组10只。模型组、常规组、双固一通组和中成药组切除双侧卵巢后常规饲养,造成实验性PMO动物模型。90天后常规组、双固一通组采用电针治疗,中成药组早晚予仙灵骨葆胶囊灌胃治疗(早晚以0.4g/次灌胃,药液量以生理盐水溶解,调整至3m1),对照组、模型组早晚予生理盐水3m1灌胃,用药期间常规饲养。疗程均为8周。电针治疗(采用四川恒明科技开发有限公司生产HM-6805型经穴治疗仪,疏密波8～80Hz,疏密波转换14次/分钟,电压1.5V,强度1mA左右,通电15min),每天1次,每次15分钟,留针10分钟,连续治疗6天后休息1天,共治疗8周。常规组取穴：脾俞、胃俞、肾俞,气海俞,均为双侧；双固一通组取关元、后三里(双)、肾俞(双)、膈俞(双)、大杼(双)。用全自动生化仪测定血清钙(calcium, Ca)、磷(phosphorus,P)、碱性磷酸酶(alkaline phosphatase, ALP)和尿钙、尿磷、尿肌酐；用放射免疫法测定血骨钙素(Osteocalcin, BGP);用酶联免疫法(Enzyme-Linked Immunosorbnent Assay, ELISA)测定尿脱氧吡啶啉(Deoxypyridinoline, DPD)的含量；用化学发光免疫分析法检测雌二醇(estradiol,E2); ELISA法检测白细胞介素(interletukin, IL)-6、巨噬细胞集落刺激因子(macrophage colony stimulating factor,M-CSF)、OPG、RANKL、RANK;双能x线骨密度仪检测骨密度(bone mass density, BMD); HE染色观察大鼠骨组织形态学的变化；反转录聚合酶链式反应(Polymerase chain reaction, RT-PCR)法检测M-CSF、OPG、RANKL-mRNA表达及OPG/RANKL。大鼠因造模手术、麻醉、灌胃死亡,取材时各组大鼠数量如下：对照组8只,模型组6只,中成药组6只,常规组6只,双固一通组7只。
结果
1模型组血Ca值明显降低、血P值明显升高、血ALP值明显升高、BGP明显升高,有非常显著性差异(P<0.01)。与模型组比较,双固一通组和中成药组血Ca明显升高、血P明显降低、血ALP明显降低,BGP明显升高有非常显著性差异(P<0.01)；双固一通组优于常规组(P<0.01)。
模型组尿Ca/Cr、P/Cr比值明显升高,有非常显著性差异(P<0.01)；与模型组比较,各组Ca/Cr、P/Cr比值均降低,常规组有非常显著性差异(P<0.01),双固一通组Ca/Cr有非常显著性差异(P<0.01),P/Cr有显著性差异(P<0.05)；双固一通组与中成药组和常规组比,无显著性差异(P>0.05)。
模型组尿DPD明显升高,有显著性差异(P<0.05)。与模型组比较,双固一通组尿DPD含量明显降低,有非常显著性差异(P<0.01)；双固一通组与中成药组和常规组比,无显著性差异(P>0.05)。
模型组血Ca明显降低、而血P、ALP值明显升高、血BGP明显升高(P<0.01)；尿Ca/Cr、P/Cr明显升高(P<0.01),尿DPD明显升高(P<0.05)。说明去卵巢骨质疏松症模型大鼠呈现高骨转化率,骨吸收增加,伴随骨形成代偿性增加,骨量减少,预示骨密度降低,与临床常见的PMO女性的骨高转换率极相似,提示造模成功。而“双固一通”针灸治疗后,BGP显著升高,提示成骨细胞(OB)活性增强,骨形成增加。双固一通组、中成药组均可升高血钙,降低血磷,降低尿Ca/Cr、尿P/Cr、DPD；常规组可升高血钙,降低尿Ca/Cr、尿P/Cr、DPD,对于血P无明显的降低作用。说明中医药治疗可以调节Ca、P代谢,促进骨形成,减缓骨吸收。
2模型组腰椎BMD明显降低,有非常显著性差异(P<0.01)。与模型组比较,各治疗组腰椎BMD均明显升高,有非常显著性差异(P<0.01)。与双固一通组比较,有显著性差异(P<0.05)。与对照组比较,模型组股骨BMD明显降低,有非常显著性差异(P<0.01)。与模型组比较,各治疗组股骨BMD均明显升高,有显著性差异(P<0.05)；与双固一通组比较,各组无显著性差异(P>0.05)。
3光镜观察结果显示：模型组骨小梁稀疏、细、中断点多、间距宽,部分区域出现较大的空白区域。常规组、中成药组、双固一通组的骨小梁增多、增粗、间隙变窄,中断点减少,三组间的区别不明显。双固一通的骨小梁排列密集,相互之间的连接明显增多,宽度增宽,体积增大,间隙变窄。
4模型组血清IL-6明显升高,E2明显降低,有非常显著性差异(P<0.01)。与模型组比较,各治疗组血清IL-6均降低,E2明显升高,有非常显著性差异(P<0.01)。与中成药组比较,双固一通组和常规组血E2无显著性差异(P>0.05)。双固一通组优于常规组和中成药组(P<0.01)。在本实验中模型组E2水平降低,IL-6含量增高,与既往的研究结果一致。“双固一通”针灸治疗后,大鼠血E2显著升高、IL-6显著下降(P<0.05),双固一通组优于常规组和中成药组。表明“双固一通”针法治疗能够升高雌激素,抑制IL-6分泌,抑制OC的活性,促进骨的形成。
5模型组血M-CSF明显升高、OPG明显降低、RANKL明显降低、RANK值明显降低,有非常显著性差异(P<0.01)；与模型组比较,双固一通组、常规组和中成药组M-CSF明显降低、OPG值明显升高、RANK明显升高,有非常显著性差异(P<0.01)；与模型组比较,中成药组血清RANKL升高,常规组血清RANKL有降低趋势,但均无显著性差异。双固一通组优于常规组和中成药组。说明针刺可以通过提高血OPG、RANKL、RANK的含量,降低M-CSF,从而抑制破骨细胞(osteoclast,OC)的骨吸收来减少骨量的丢失,且“双固一通,,针法优于其它方法。
6模型组骨M-CSFmRNA表达较对照组明显升高,有非常显著性差异(P<0.01)。与模型组比较,各治疗组M-CSFmRNA表达均降低,有非常显著性差异(P<0.01)。与双固一通组比较,常规组M-CSFmRNA表达升高,有显著性差异(P<0.05),中成药组有非常显著性差异(P<0.01)。中成药组、常规组、双固一通组均有效,但双固一通组效最好。
模型组骨OPGmRNA表达较对照组明显降低,有非常显著性差异(P<0.01)。与模型组比较,各治疗组OPGmRNA表达均升高,有非常显著性差异(P<0.01)。与中成药组和常规组比较,双固一通组有非常显著性差异(P<0.01),与对照组比较,无显著性差异(P>0.05)。中成药组、常规组、双固一通组均有效,但双固一通组效最好。
模型组骨RANKLmRNA表达较对照组明显降低,有非常显著性差异(P<0.01)。与模型组比较,双固一通组骨RANKLmRNA表达升高,有非常显著性差异(P<0.01),中成药组和常规组RANKLmRNA表达与模型组比无显著性差异(P>0.05)。双固一通组与中成药组比有显著性差异(P<0.05)。双固一通组有效,中成药组和常规组均无效。
模型组骨OPG/RANKL比值较对照组显著降低,有显著性差异(P<0.05)。与模型组比,双固一通组骨OPG/RANKL比值升高,有非常显著性差异(P<0.01),中成药组与模型组比有显著性差异(P<0.05),常规组与模型组比无显著性差异(P>0.05)。中成药组与双固一通组均有效,但双固一通组效更好。
本研究结果表明：模型组骨M-CSFmRNA表达明显升高(P<0.01),提示OC生成增加；各治疗组M-CSFmRNA表达均降低(P<0.01),表明中医药治疗尤其是“双固一通”针法可以抑制OC数量,或降低OC活性,减缓骨吸收。模型组骨OPG、RANKLmRNA表达显著降低(P<0.01),提示OPG蛋白表达降低,破骨吸收增加；RANKL蛋白表达降低,OPG与RANKL结合有一定程度的阻滞OC生成的作用,而综合作用仍表现为骨吸收的增加。OPG/RANKL比值能反映成骨细胞(osteoblast, OB)的形成,比值越大,OB介导的能力越强；englixibaoweiia促进骨吸收,限制骨矿化的速度。
模型组骨OPG/RANKL比值表达较对照组明显降低,提示骨形成降低。双固一通组骨OPG、RANKLmRNA表达明显升高(P<0.01)、RANKLmRNA表达降低(P<0.01),OPG/RANKL比值明显升高(P<0.01),提示“双固一通”针法可能通过促进OPG蛋白表达,提高OB活性,通过与RANK竞争和RANKL的结合,阻止OC的生成,阻止骨吸收。
结论
通过本课题的研究,我们认为：“双固一通”针法对OPG/RANKL /RANK的调节是多环节、多途径的：
1“双固一通”针灸治疗后,BGP显著升高,提示成骨细胞活性增强,骨形成增加；血钙升高,血磷降低,尿Ca/Cr、尿P/Cr、DPD降低,提示“双固一通”针灸治疗可以通过增加胃肠吸收功能,促进对钙、磷等各种营养物质的吸收和利用,调节Ca、P代谢,降低尿Ⅰ型胶原分解产物DPD浓度,提高BGP浓度,从而抑制骨吸收、促进骨形成,最终使骨矿含量增加,维持甚至提高骨密度。
2“双固一通”针灸治疗能通过提高去卵巢骨质疏松症模型大鼠E2的水平,减少IL-6含量,加强雌激素对IL-6的抑制作用,减少OC的前体细胞形成,抑制骨吸收,表现为BMD的升高、模型大鼠骨组织形态结构的改善。
3“双固一通”针灸治疗能升高去卵巢骨质疏松症模型大鼠血清OPG、RANKL、RANK含量和降低M-CSF水平,以抑制OC的活性而减少骨吸收,减少骨量的丢失。
4“双固一通”针灸治疗能升高去卵巢骨质疏松症模型大鼠血清OPG、RANKL、RANK含量和降低M-CSF,以抑制OC的活性而减少骨吸收,减少骨量的丢失；“双固一通”针灸治疗能通过降低去卵巢骨质疏松症模型大鼠骨M-CSFmRNA表达来抑制OC数量,或降低OC活性,减缓骨吸收；通过升高骨OPGmRNA表达,升高RANKLmRNA的表达,提高OB活性,通过与RANK竞争和RANKL的结合,阻止OC的生成,阻止骨吸收；通过升高OPG/RANKL比值,调节OPG/RANKL/RANK,能抑制OC活性,拮抗骨吸收。
Objective
To observe the effect of 'shuang gu yi tong' acupuncture therapy on OPG/RANKL/RANK in the rats of postmenopausal osteoporosis (PMO), investigate the method and working mechanism, and obtain the new way of acupuncture therapy and the Experiment basis.
Methods:
Experiment methods:Fifty SD rats were randomly divided into five groups:control group, model group, common acupuncture group (abbreviated as common group),'shuang gu yi tong' acupuncture group (abbreviated as shuang gu yi tong group), Herb group. The rats of model group, common group, shuang gu yi tong group, Herb group were ovariectomized to be the PMO Animal model. After 90 days, common groupand shuang gu yi tong group were treated with Electroacupuncture(Qd), Herb group was treated with Xianlinggubao (0.4g, Bid). Control group and model group were treated wi th NS. The course of treatment was 8 weeks. Electroacupuncture was treated everyday for 15 minutes. Pishu, Weishu, Shenshu, Qihaishu (double) were treated for common group; Guanyuan, Housanli, Shenshu, Geshu, Dazhu were treated for Shuang gu yi tong group. After the experiment, we detected ALP, E2, IL-6, BGP, Ca, P, M-CSF, OPG, RANKL, RANK in the blood and Ca, P, Ca/Cr, DPD in the urine; We detected BMD; We detected M-CSF, OPG, RANKL-mRNA and OPG/RANKL with RT-PCR.
Results
1 The level of Ca in the blood of model group was decreased, P, ALP and BGP was increased. There was significant difference between model group and control group (P<0.01). The level of Ca in the blood of Shuang gu yi tong group was increased, P, ALP and BGP was decreased. Shuang gu yi tong group was better than common group.
The level of Ca/Cr, P/Cr in the urine of model group was increased. There was significant difference between model group and control group(P<0.01). The level of Ca/Cr, P/Cr was decreased. There were no significant difference between Shuang gu yi tong group, herb group and common group (P>0.05).
The level of DPD in the urine of model group was increased. There was significant difference between model group and control group (P<0.05). The level of DPD of was decreased. There was significant difference between model group and Shuang gu yi tong group (P<0.01).There was no significant difference between Shuang gu yi tong group, herb group and common group (P>0.05).
2 The BMD of lumbar and femur was decreased in model group. There was significant difference between model group and all treatment groups (P<0.01, P<0.05). The BMD in all treatment groups was increased. There was significant difference between Shuang gu yi tong group and other treatment groups on lumbar (P<0.05). There was no significant difference between Shuang gu yi tong group and other treatment groups on femur (P> 0.05)
3 To observe the morphological structure with light microscope. The bone trabe cula of model group was raritas, trifling. There was many breakpoint.The dist was wide. The bone trabe cula of all treatment groups was mult, thickening. The breakpoint and blank was improved. Shuang gu yi tong group was better than common group and herb group.
4 The level of IL-6 was increased, E2 was decreased in model group. There was significant difference between model group and control group (P<0.01). The level of IL-6 in all treatment groups was decreased, E2 was increased. There was significant difference between model group and control group (P<0.01). Shuang gu yi tong group was better than common group and herb group.
5 The level of M-CSF in the blood was increased, OPG was decreased, RANKL was decreased in model group. There was significant difference between model group and control group (P<0.01). The level of M-CSF in all treatment groups was decreased, OPG was increased, RANK was increased. There were significant difference between herb group, common group and model group(P<0.01). Shuang gu yi tong group was better than common group and herb group.
6 The expression of M-CSFmRNA in the bone of model group was increased (P<0.01). The expression of M-CSFmRNA in all treatment groups was decreased. There was significant difference between common group and Shuang gu yi tong group (P<0.05). There was significant difference between herb group and Shuang gu yi tong group (P<0.01). Shuang gu yi tong group was better than common group and herb group.
The expression of OPGmRNA in the bone of model group was decreased. There was significant difference between model group and control group (P<0.01). The expression of OPGmRNA in all treatment groups was increased. There were significant difference between herb group, common group and model group (P<0.01). Shuang gu yi tong group was better than common group and herb group.
The expression of RANKLmRNA in the bone of model group was decreased. There was significant difference between model group and control group (P<0.01).The expression of RANKLmRNA of Shuang gu yi tong group was increased. There was significant difference between model group and Shuang gu yi tong group (P<0.01). Shuang gu yi tong group was better than common group and Herb group.
The expression of OPG/RANKL in the bone of model group was decreased. There was significant difference between model group and control group (P<0.05).The expression of RANKLmRNA of Shuang gu yi tong group was increased. There was significant difference between model group and Shuang gu yi tong group (P<0.01). Shuang gu yi tong group was better than common group and herb group.
Conclusion:
1 Shuang gu yi tong acupuncture therapy could increase BGP, Ca, increase P, Ca/Cr, P/Cr, DPD in the Urine to regulate Ca, P metabolism.
2 Shuang gu yi tong acupuncture therapy could increase E2, decrease IL-6 to increase BMD, to improve the morphological structure.
3 Shuang gu yi tong acupuncture therapy could increase OPG, RANKL, RANK, decrease M-CSF to inhibit the activity of OC, to reduce the loss of bone mass.
4 Shuang gu yi tong acupuncture therapy could increase the expression of OPGmRNA, RANKLmRNA, OPG/RANKL, decrease M-CSFmRNA, increase the activity of osteoblasts, prevent bone resorption.
观察“双固一通”针法对去卵巢绝经后骨质疏松症(postmenopausal osteoporosis, PMO)模型大鼠调节骨吸收平衡的相关细胞因子系统——护骨素(osteoprotegerin, OPG)/核因子κB受体活化因子配体(receptor activator of nuclear factor-κB ligand,RANKL)/核因子κB受体活化因子(receptor activator of nuclear factor-κB, RANK)系统的影响,进一步探讨“双固一通”针法治疗本病的作用机制,为针灸治疗PMO提供新的思路和方法,为临床预防和治疗PMO提供实验依据。
方法
依随机原则将50只SD大鼠分为对照组、模型组、常规取穴针刺组(简称常规组)、“双固一通”针刺组(简称双固一通组)和中成药治疗组(简称中成药组),每组10只。模型组、常规组、双固一通组和中成药组切除双侧卵巢后常规饲养,造成实验性PMO动物模型。90天后常规组、双固一通组采用电针治疗,中成药组早晚予仙灵骨葆胶囊灌胃治疗(早晚以0.4g/次灌胃,药液量以生理盐水溶解,调整至3m1),对照组、模型组早晚予生理盐水3m1灌胃,用药期间常规饲养。疗程均为8周。电针治疗(采用四川恒明科技开发有限公司生产HM-6805型经穴治疗仪,疏密波8～80Hz,疏密波转换14次/分钟,电压1.5V,强度1mA左右,通电15min),每天1次,每次15分钟,留针10分钟,连续治疗6天后休息1天,共治疗8周。常规组取穴：脾俞、胃俞、肾俞,气海俞,均为双侧；双固一通组取关元、后三里(双)、肾俞(双)、膈俞(双)、大杼(双)。用全自动生化仪测定血清钙(calcium, Ca)、磷(phosphorus,P)、碱性磷酸酶(alkaline phosphatase, ALP)和尿钙、尿磷、尿肌酐；用放射免疫法测定血骨钙素(Osteocalcin, BGP);用酶联免疫法(Enzyme-Linked Immunosorbnent Assay, ELISA)测定尿脱氧吡啶啉(Deoxypyridinoline, DPD)的含量；用化学发光免疫分析法检测雌二醇(estradiol,E2); ELISA法检测白细胞介素(interletukin, IL)-6、巨噬细胞集落刺激因子(macrophage colony stimulating factor,M-CSF)、OPG、RANKL、RANK;双能x线骨密度仪检测骨密度(bone mass density, BMD); HE染色观察大鼠骨组织形态学的变化；反转录聚合酶链式反应(Polymerase chain reaction, RT-PCR)法检测M-CSF、OPG、RANKL-mRNA表达及OPG/RANKL。大鼠因造模手术、麻醉、灌胃死亡,取材时各组大鼠数量如下：对照组8只,模型组6只,中成药组6只,常规组6只,双固一通组7只。
结果
1模型组血Ca值明显降低、血P值明显升高、血ALP值明显升高、BGP明显升高,有非常显著性差异(P<0.01)。与模型组比较,双固一通组和中成药组血Ca明显升高、血P明显降低、血ALP明显降低,BGP明显升高有非常显著性差异(P<0.01)；双固一通组优于常规组(P<0.01)。
模型组尿Ca/Cr、P/Cr比值明显升高,有非常显著性差异(P<0.01)；与模型组比较,各组Ca/Cr、P/Cr比值均降低,常规组有非常显著性差异(P<0.01),双固一通组Ca/Cr有非常显著性差异(P<0.01),P/Cr有显著性差异(P<0.05)；双固一通组与中成药组和常规组比,无显著性差异(P>0.05)。
模型组尿DPD明显升高,有显著性差异(P<0.05)。与模型组比较,双固一通组尿DPD含量明显降低,有非常显著性差异(P<0.01)；双固一通组与中成药组和常规组比,无显著性差异(P>0.05)。
模型组血Ca明显降低、而血P、ALP值明显升高、血BGP明显升高(P<0.01)；尿Ca/Cr、P/Cr明显升高(P<0.01),尿DPD明显升高(P<0.05)。说明去卵巢骨质疏松症模型大鼠呈现高骨转化率,骨吸收增加,伴随骨形成代偿性增加,骨量减少,预示骨密度降低,与临床常见的PMO女性的骨高转换率极相似,提示造模成功。而“双固一通”针灸治疗后,BGP显著升高,提示成骨细胞(OB)活性增强,骨形成增加。双固一通组、中成药组均可升高血钙,降低血磷,降低尿Ca/Cr、尿P/Cr、DPD；常规组可升高血钙,降低尿Ca/Cr、尿P/Cr、DPD,对于血P无明显的降低作用。说明中医药治疗可以调节Ca、P代谢,促进骨形成,减缓骨吸收。
2模型组腰椎BMD明显降低,有非常显著性差异(P<0.01)。与模型组比较,各治疗组腰椎BMD均明显升高,有非常显著性差异(P<0.01)。与双固一通组比较,有显著性差异(P<0.05)。与对照组比较,模型组股骨BMD明显降低,有非常显著性差异(P<0.01)。与模型组比较,各治疗组股骨BMD均明显升高,有显著性差异(P<0.05)；与双固一通组比较,各组无显著性差异(P>0.05)。
3光镜观察结果显示：模型组骨小梁稀疏、细、中断点多、间距宽,部分区域出现较大的空白区域。常规组、中成药组、双固一通组的骨小梁增多、增粗、间隙变窄,中断点减少,三组间的区别不明显。双固一通的骨小梁排列密集,相互之间的连接明显增多,宽度增宽,体积增大,间隙变窄。
4模型组血清IL-6明显升高,E2明显降低,有非常显著性差异(P<0.01)。与模型组比较,各治疗组血清IL-6均降低,E2明显升高,有非常显著性差异(P<0.01)。与中成药组比较,双固一通组和常规组血E2无显著性差异(P>0.05)。双固一通组优于常规组和中成药组(P<0.01)。在本实验中模型组E2水平降低,IL-6含量增高,与既往的研究结果一致。“双固一通”针灸治疗后,大鼠血E2显著升高、IL-6显著下降(P<0.05),双固一通组优于常规组和中成药组。表明“双固一通”针法治疗能够升高雌激素,抑制IL-6分泌,抑制OC的活性,促进骨的形成。
5模型组血M-CSF明显升高、OPG明显降低、RANKL明显降低、RANK值明显降低,有非常显著性差异(P<0.01)；与模型组比较,双固一通组、常规组和中成药组M-CSF明显降低、OPG值明显升高、RANK明显升高,有非常显著性差异(P<0.01)；与模型组比较,中成药组血清RANKL升高,常规组血清RANKL有降低趋势,但均无显著性差异。双固一通组优于常规组和中成药组。说明针刺可以通过提高血OPG、RANKL、RANK的含量,降低M-CSF,从而抑制破骨细胞(osteoclast,OC)的骨吸收来减少骨量的丢失,且“双固一通,,针法优于其它方法。
6模型组骨M-CSFmRNA表达较对照组明显升高,有非常显著性差异(P<0.01)。与模型组比较,各治疗组M-CSFmRNA表达均降低,有非常显著性差异(P<0.01)。与双固一通组比较,常规组M-CSFmRNA表达升高,有显著性差异(P<0.05),中成药组有非常显著性差异(P<0.01)。中成药组、常规组、双固一通组均有效,但双固一通组效最好。
模型组骨OPGmRNA表达较对照组明显降低,有非常显著性差异(P<0.01)。与模型组比较,各治疗组OPGmRNA表达均升高,有非常显著性差异(P<0.01)。与中成药组和常规组比较,双固一通组有非常显著性差异(P<0.01),与对照组比较,无显著性差异(P>0.05)。中成药组、常规组、双固一通组均有效,但双固一通组效最好。
模型组骨RANKLmRNA表达较对照组明显降低,有非常显著性差异(P<0.01)。与模型组比较,双固一通组骨RANKLmRNA表达升高,有非常显著性差异(P<0.01),中成药组和常规组RANKLmRNA表达与模型组比无显著性差异(P>0.05)。双固一通组与中成药组比有显著性差异(P<0.05)。双固一通组有效,中成药组和常规组均无效。
模型组骨OPG/RANKL比值较对照组显著降低,有显著性差异(P<0.05)。与模型组比,双固一通组骨OPG/RANKL比值升高,有非常显著性差异(P<0.01),中成药组与模型组比有显著性差异(P<0.05),常规组与模型组比无显著性差异(P>0.05)。中成药组与双固一通组均有效,但双固一通组效更好。
本研究结果表明：模型组骨M-CSFmRNA表达明显升高(P<0.01),提示OC生成增加；各治疗组M-CSFmRNA表达均降低(P<0.01),表明中医药治疗尤其是“双固一通”针法可以抑制OC数量,或降低OC活性,减缓骨吸收。模型组骨OPG、RANKLmRNA表达显著降低(P<0.01),提示OPG蛋白表达降低,破骨吸收增加；RANKL蛋白表达降低,OPG与RANKL结合有一定程度的阻滞OC生成的作用,而综合作用仍表现为骨吸收的增加。OPG/RANKL比值能反映成骨细胞(osteoblast, OB)的形成,比值越大,OB介导的能力越强；englixibaoweiia促进骨吸收,限制骨矿化的速度。
模型组骨OPG/RANKL比值表达较对照组明显降低,提示骨形成降低。双固一通组骨OPG、RANKLmRNA表达明显升高(P<0.01)、RANKLmRNA表达降低(P<0.01),OPG/RANKL比值明显升高(P<0.01),提示“双固一通”针法可能通过促进OPG蛋白表达,提高OB活性,通过与RANK竞争和RANKL的结合,阻止OC的生成,阻止骨吸收。
结论
通过本课题的研究,我们认为：“双固一通”针法对OPG/RANKL /RANK的调节是多环节、多途径的：
1“双固一通”针灸治疗后,BGP显著升高,提示成骨细胞活性增强,骨形成增加；血钙升高,血磷降低,尿Ca/Cr、尿P/Cr、DPD降低,提示“双固一通”针灸治疗可以通过增加胃肠吸收功能,促进对钙、磷等各种营养物质的吸收和利用,调节Ca、P代谢,降低尿Ⅰ型胶原分解产物DPD浓度,提高BGP浓度,从而抑制骨吸收、促进骨形成,最终使骨矿含量增加,维持甚至提高骨密度。
2“双固一通”针灸治疗能通过提高去卵巢骨质疏松症模型大鼠E2的水平,减少IL-6含量,加强雌激素对IL-6的抑制作用,减少OC的前体细胞形成,抑制骨吸收,表现为BMD的升高、模型大鼠骨组织形态结构的改善。
3“双固一通”针灸治疗能升高去卵巢骨质疏松症模型大鼠血清OPG、RANKL、RANK含量和降低M-CSF水平,以抑制OC的活性而减少骨吸收,减少骨量的丢失。
4“双固一通”针灸治疗能升高去卵巢骨质疏松症模型大鼠血清OPG、RANKL、RANK含量和降低M-CSF,以抑制OC的活性而减少骨吸收,减少骨量的丢失；“双固一通”针灸治疗能通过降低去卵巢骨质疏松症模型大鼠骨M-CSFmRNA表达来抑制OC数量,或降低OC活性,减缓骨吸收；通过升高骨OPGmRNA表达,升高RANKLmRNA的表达,提高OB活性,通过与RANK竞争和RANKL的结合,阻止OC的生成,阻止骨吸收；通过升高OPG/RANKL比值,调节OPG/RANKL/RANK,能抑制OC活性,拮抗骨吸收。
Objective
To observe the effect of 'shuang gu yi tong' acupuncture therapy on OPG/RANKL/RANK in the rats of postmenopausal osteoporosis (PMO), investigate the method and working mechanism, and obtain the new way of acupuncture therapy and the Experiment basis.
Methods:
Experiment methods:Fifty SD rats were randomly divided into five groups:control group, model group, common acupuncture group (abbreviated as common group),'shuang gu yi tong' acupuncture group (abbreviated as shuang gu yi tong group), Herb group. The rats of model group, common group, shuang gu yi tong group, Herb group were ovariectomized to be the PMO Animal model. After 90 days, common groupand shuang gu yi tong group were treated with Electroacupuncture(Qd), Herb group was treated with Xianlinggubao (0.4g, Bid). Control group and model group were treated wi th NS. The course of treatment was 8 weeks. Electroacupuncture was treated everyday for 15 minutes. Pishu, Weishu, Shenshu, Qihaishu (double) were treated for common group; Guanyuan, Housanli, Shenshu, Geshu, Dazhu were treated for Shuang gu yi tong group. After the experiment, we detected ALP, E2, IL-6, BGP, Ca, P, M-CSF, OPG, RANKL, RANK in the blood and Ca, P, Ca/Cr, DPD in the urine; We detected BMD; We detected M-CSF, OPG, RANKL-mRNA and OPG/RANKL with RT-PCR.
Results
1 The level of Ca in the blood of model group was decreased, P, ALP and BGP was increased. There was significant difference between model group and control group (P<0.01). The level of Ca in the blood of Shuang gu yi tong group was increased, P, ALP and BGP was decreased. Shuang gu yi tong group was better than common group.
The level of Ca/Cr, P/Cr in the urine of model group was increased. There was significant difference between model group and control group(P<0.01). The level of Ca/Cr, P/Cr was decreased. There were no significant difference between Shuang gu yi tong group, herb group and common group (P>0.05).
The level of DPD in the urine of model group was increased. There was significant difference between model group and control group (P<0.05). The level of DPD of was decreased. There was significant difference between model group and Shuang gu yi tong group (P<0.01).There was no significant difference between Shuang gu yi tong group, herb group and common group (P>0.05).
2 The BMD of lumbar and femur was decreased in model group. There was significant difference between model group and all treatment groups (P<0.01, P<0.05). The BMD in all treatment groups was increased. There was significant difference between Shuang gu yi tong group and other treatment groups on lumbar (P<0.05). There was no significant difference between Shuang gu yi tong group and other treatment groups on femur (P> 0.05)
3 To observe the morphological structure with light microscope. The bone trabe cula of model group was raritas, trifling. There was many breakpoint.The dist was wide. The bone trabe cula of all treatment groups was mult, thickening. The breakpoint and blank was improved. Shuang gu yi tong group was better than common group and herb group.
4 The level of IL-6 was increased, E2 was decreased in model group. There was significant difference between model group and control group (P<0.01). The level of IL-6 in all treatment groups was decreased, E2 was increased. There was significant difference between model group and control group (P<0.01). Shuang gu yi tong group was better than common group and herb group.
5 The level of M-CSF in the blood was increased, OPG was decreased, RANKL was decreased in model group. There was significant difference between model group and control group (P<0.01). The level of M-CSF in all treatment groups was decreased, OPG was increased, RANK was increased. There were significant difference between herb group, common group and model group(P<0.01). Shuang gu yi tong group was better than common group and herb group.
6 The expression of M-CSFmRNA in the bone of model group was increased (P<0.01). The expression of M-CSFmRNA in all treatment groups was decreased. There was significant difference between common group and Shuang gu yi tong group (P<0.05). There was significant difference between herb group and Shuang gu yi tong group (P<0.01). Shuang gu yi tong group was better than common group and herb group.
The expression of OPGmRNA in the bone of model group was decreased. There was significant difference between model group and control group (P<0.01). The expression of OPGmRNA in all treatment groups was increased. There were significant difference between herb group, common group and model group (P<0.01). Shuang gu yi tong group was better than common group and herb group.
The expression of RANKLmRNA in the bone of model group was decreased. There was significant difference between model group and control group (P<0.01).The expression of RANKLmRNA of Shuang gu yi tong group was increased. There was significant difference between model group and Shuang gu yi tong group (P<0.01). Shuang gu yi tong group was better than common group and Herb group.
The expression of OPG/RANKL in the bone of model group was decreased. There was significant difference between model group and control group (P<0.05).The expression of RANKLmRNA of Shuang gu yi tong group was increased. There was significant difference between model group and Shuang gu yi tong group (P<0.01). Shuang gu yi tong group was better than common group and herb group.
Conclusion:
1 Shuang gu yi tong acupuncture therapy could increase BGP, Ca, increase P, Ca/Cr, P/Cr, DPD in the Urine to regulate Ca, P metabolism.
2 Shuang gu yi tong acupuncture therapy could increase E2, decrease IL-6 to increase BMD, to improve the morphological structure.
3 Shuang gu yi tong acupuncture therapy could increase OPG, RANKL, RANK, decrease M-CSF to inhibit the activity of OC, to reduce the loss of bone mass.
4 Shuang gu yi tong acupuncture therapy could increase the expression of OPGmRNA, RANKLmRNA, OPG/RANKL, decrease M-CSFmRNA, increase the activity of osteoblasts, prevent bone resorption.
引文
[1]刑淑敏.绝经后骨质疏松症的防治.实用妇产科杂志.,2004；20(3)：132-134
[2]李恩.原发性骨质疏松发病的相关因素.中国骨质疏松杂志,1997；3(2)：1-2
[3]刘忠厚.骨质疏松学.北京：科学技术出版社.1998,第1版：929
[4]李瑛,邹季,任捷.退行性骨质疏松症诊断.中外健康文摘：医药月刊,2008；5(2)：93-94
[5]刘忠厚主编.骨矿与临床.北京：科学技术出版社.2006,第1版：7
[6]Li X,Pilbeam CC,Pan l,et al.Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.Bone,2002;30(4):567-573
[7]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget's disease.N Engl J Med,2002;347(3):175-184
[8]曾晓峰.骨代谢与免疫功能的相互调节.细胞与分子免疫学杂志,2003；19(6)：629-632
[9]武兆忠,刘敏,冯鉴强.RNA干扰抑制雌激素受体α亚基对雌激素诱导人成骨样细胞护骨素表达的影响.中国老年学杂志,2005；25(2)：179-182
[10]Jilka RL.Cytokines,bone remodeling,and estrogen deficiency:a 1998 update.Bone,1998;23:75-81
[11]Writing group for the women's health initiative investigations.Risks and benefits of estrogestin in healthy Postmenopausal women:principal results from the women's health initiative randomized controlled trial. JAMA,2002;288(3):321-333
[12]陈名道.美国停止对健康绝经期后妇女激素替代治疗的临床试验.国外医学内分泌学分册,2002；22(5)：34
[13]金肖青,文晓林,于澎,等.电针治疗原发性骨质疏松症临床32例分析.中医药学刊,2003；21(4)：70-71
[14]刘献祥,吴明霞,吴炳煌,等.针灸对原发性骨质疏松症影响的实验和临床研究.中国骨伤,2000；13(9)：519-521
[15]张华,冯新送,庄洪等.中医对原发性骨质疏松症的认识及辨证施治研究.中医正骨,2001；13(3)：55
[16]周晓莉,鲍圣涌,王华.“双固一通”针灸疗法对绝经后骨质疏松症骨密度的影响.湖北中医杂志,2005；27(6)：49-50
[17]周晓莉,鲍圣涌,王华.“双固一通”针法治疗绝经后骨质疏松症的临床研究.医学综述杂志,2007；13(23)：1852-1854.
[18]周晓莉,刘品莉,姜青松,等.“双固一通”针法治疗绝经后骨质疏松症的临床研究.中国骨质疏松杂志,2008；14(3)：204-207.
[19]周晓莉.”双固一通”针法对绝经后骨质疏松症患者的临床研究.湖北中医学院硕士毕业论文.2005
[20]鲍圣涌,王华,周晓莉.“双固一通”针法治疗绝经后骨质疏松症模型大鼠BMC、BMD及E2的影响.上海针灸杂志,2005；24(11)：28
[21]鲍圣涌,王华,王彦春,等.”双固一通”针法对绝经后骨质疏松症模型大鼠骨组织骨保护蛋白mRNA表达水平的影响.针刺研究,2006；31(3)：
[22]鲍圣涌,王华,阎德文,等.”双固一通”针法对绝经后骨质疏松症模型大鼠胰岛素样生长因子-1及组织形态学的影响.中国骨质疏松杂志,2008；14(9)：619-623
[23]黄永南.“双固一通”针法对绝经后骨质疏松症模型大鼠的骨密度、免疫球蛋白及RANKLm RNA表达水平的影响.湖北中医学院硕士毕业论文.2008
[1]华兴邦,李辞蓉,周浩良,等.大鼠穴位图谱的研制.实验动物与动物实验,1991；1：1-5
[2]林文注主编.实验针灸学.上海：上海科学技术出版社,1999,第一版：288-290
[3]孙敬方.动物实验方法学.北京：人民卫生出版社,2011,第一版：357
[4]Mul lender MG, Van der Meer DD, and Huiskes R, et al. Osteocyte density changes in aging and osteoporosis. Bone,1996; 18,109
[5]Rogers A, Eastell RA, Eastell R.Biochemical makers as predictors of rats of bone loss after menopause. J Bone Miner Res,2000;15(7):1398-1404
[6]王萍玉,张亨菊.骨质疏松症的膳食危险因素研究进展.卫生研究,2003；32(1)：81-83
[7]刘忠厚.骨质疏松症.北京：科学出版社,1998,第一版：67-78
[8]薛延等.骨质疏松症诊断与治疗指南.北京：科学出版社,1999,第一版：217
[9]安胜军,杨学辉,李恩.雌激素与骨质疏松症.中国骨质疏松杂志,1999；5(3)：81-82
[10]王智兴,李群.成骨生长肽对成骨细胞样细胞的成骨影响.中华骨科杂志,2000；20(1)：58-60
[11]周晓莉,刘品莉,姜青松,等.“双固一通”针法治疗绝经后骨质疏松症的临床研究.中国骨质疏松杂志,2008；14(3)：204-207
[12]Hasegawa J, Nagashima M, Yamamoto M, et al. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritias. J Rheumatol,2003;30(3):474-479
[13]Weaver CM, Peacock M, Martin BR, et al. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem,1994; 40:2022-25
[14]Price PA, Williamson MK, Lothringer JW. Origin of the Vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem,1981;256(24):12760-12766
[15]Auschka PV, Lian JB, Cole DEC, et al. Osteocalcin and matrix Gla Protein; vitamin K-dependent proteins in bone. Physiol Rev,1989;69: 990-1047
[16]黄江渝,胡汶竹.血清骨钙素水平检测的临床应用现状.现代预防医学,2007；34(9)：1674-1675
[17]冯莉,杨静华,李熙明,等.尿脱氧吡啶啉用于绝经前子宫切除妇女骨代谢变化检测的研究.中国骨质疏松杂志,2007；13(11)：791-793
[18]马文松,刘磊,朱小弟等.骨质疏松血清IL-6与骨代谢生化指标的变化.中国骨质疏松杂志,2002；8(4)：327-328
[19]刘忠厚.骨质疏松症.北京：科学出版社,1998,第一版：179
[20]庞勇,赵利华,农泽宁,等.针灸治疗原发性骨质疏松症临床研究.上海针灸杂志,2008；27(12)：144-147
[21]何国栋,牛伟新,刘寒,等.电针足三里穴对兔胃肠道平滑肌电活动的影响及与胃动素、胆囊收缩素关系的研究.中国临床医学,2007；14(4)：504-506
[22]肖少卿.浅谈足三里养生保健的意义与应用.江苏中医,1998；19(7)：35
[23]贾育松.穴位注射治疗绝经后骨质疏松症初探.中国骨质疏松杂志,2003；9(23)：171-149
[1]秦岭,张戈(译).美国国家卫生院有关骨质疏松症的预防、诊断和治疗的共识文件.中国骨质疏松杂志.2002；8(1)：90-93
[2]柴生廷,庄洪,魏合伟.骨质疏松性骨折流行病学研究进展.中医正骨,2004；16(2)：55-56
[3]朴俊红,庞莲萍,刘忠厚,等.中国人口状况及原发性骨质疏松症诊断标准和发生率.中国骨质疏松杂志,2002；8(1)：1-7
[4]朱国英,王洪复,王伟华,等.绝经后骨质疏松症的发生率与诊断标准研究.中华实用医学杂志,2002；4(17)：1-4
[5]林芸,陈党生.骨密度测量部位对女性骨质疏松症诊断的影响.中国现代实用医学杂志,2004；3(15)：9-11
[6]唐海,李永刚,陈浩.骨密度测量技术的临床应用及评价.实用糖尿病杂志,2006；2(4)：9-11
[7]周久贸,刘浩,蒋森,等.沈阳地区2288例骨密度测定及骨质疏松症发病率分析.中国临床医学影像杂志,2008；19(2)：121-124
[8]Hawler GA,Jamal SA,Ridout R,et al.A clinical prediction rule to identify premenopausal women with low bone mass.Osteoporos Int.2002;13:400-406
[9]周晓莉,鲍圣涌,王华.“双固一通”针法治疗绝经后骨质疏松症的临床研究.医学综述,2007；13(23)：1852-1854
[1]崔轶,雷伟,吴子祥,等.骨质疏松大动物模型的研究进展.脊柱外科杂志,2010；8(5)：316-320
[2]王晓,梅其炳,刘莉,等.骨质疏松动物模型的复制与评价.中国骨质疏松杂志,2007；13(2)：141-145
[3]沈辉,潘时中.大鼠切除卵巢骨质疏松模型的实验研究.福建医科大学学报,2004；38(2)：152-154
[4]D. D. Thompson, H. A. Simmons, C. M. Pirie, et al. FDA guidelines and animal models for osteoporosis.Bone,1995; 17(10):25
[5]Kavuncu V, Sahin S, Baydas G, et al. A comparison of estrogen and two different doses of calcitonin in ovariectomized rats. Yonsei Med J, 2003;44(3):508-516
[6]萨仁,王富春,池岛乔.针灸治疗实验性骨质疏松症对肿瘤坏死因子基因 表达的影响.针刺研究,2004；29(2)：140-144
[7]张洪,崔德芝,陈韶坤.补肾坚骨胶囊对去势大鼠骨代谢指标的影响.浙江中西医结合杂志,2004；14(12)：729-730
[8]黄洪,田成功.邦得林治疗雄性骨质疏松大鼠的实验研究.南京医科大学,2001；21(1)：47
[9]武密山,赵素芝,李恩.抗骨松穴位贴剂对骨质疏松大鼠模型作用机理研究.上海中医药大学学报,2001；15(1)：45
[10]周丽,邓伟民,韩丽萍.补肾壮骨颗粒对维甲酸致骨质疏松大鼠骨组织计量学的影响.实验动物科学,2009；26(3)：7-10
[11]乔伟伟,许兰文,杨幼明,等.大鼠营养干预性骨质疏松症模型的研究.上海实验动物科学,2002；22(3)：145-151
[12]李晓康,周涛,王志彬,等.针刺对损毁弓状核大鼠所致骨质疏松症的干预研究.天津中医药,2007；24(5)：380-382
[13]洪志勇,刘爱平.制作骨质疏松症大鼠模型的甲状旁腺切除法.上海实验动物科学,1996；16(2)：85-86
[14]Masse PG, Boskey AL, Ziv I, et al. Chemical and biomechanical characterization of hyperhomocysteinemic bone disease in an animal model. BMC Musculoskelet Disord,2003;4(1):2
[15]郑成杰,李洪洋,潭建三.骨磷抗去坐骨神经雄鼠骨质疏松实验研究.右江民族医学院学报,1999；21(4)：547
[16]唐学阳,刘利君,彭明惺,等.腿-尾固定法建立大鼠废用性骨质疏松模型.中国临床康复,2003；7(15)：2131-2134
[17]Rodgers JB,Monier-Faugere MC,Malluche H. Animal models for the study of bone loss after cessation of ovarian function. Bone 1993; 14(3): 369-377
[18]Kalu DN. The ovariectomized rat model of postmenopausal bone loss.Bone Miner 1991;15(3):175-191·
[19]Peng ZQ,Vaananen HK,Zhang HX,et al. Long-term effects of ovariectomy on the mechanical properties and chemical composition of rat bone. Bone,1997;20(3):207-212
[20]袁勇,钟卫军.骨质疏松症的动物实验研究进展.湖南中医药导报,2003；9(12)：50-51
[21]Wronski T J,Citron M,Danm L M.Temporal relationship between bone loss and increased bone turnover in ovariectomized rats.Calcif Tissue Int,1988,42:179
[22]郭宏,张润荃,刘洪臣,等.去势大鼠骨质疏松模型的综合评定.中华老年口腔医学杂志,2009；7(4)：196-234
[1]许咏乐.雌激素受体与绝经后骨质疏松.国外医学妇产科分册,2005；32(4)：274-277
[2]安胜军,杨学辉,李恩.雌激素与骨质疏松症.中国骨质疏松杂志,1999；5(3)：81-82
[3]齐绍霞.小剂量雌激素预防围绝经期骨质疏松症的临床观察.中国骨质疏松杂志,2008；14(7)：517-49
[4]Shevde NK, Pike JW. Estrogen moduiates the recruitment of muelopoietic cell progenitors in rat thrugh a strimal cell-independent mechanism involving apoptosis. Blood,1996; 87:2683-2693
[5]Jilka RL.Cytokines,bone remodeling,and estrogen deficiency:a 1998 update.Bone,1998;23:75-81
[6]童安莉,陈璐璐.白细胞介素6在骨吸收中的作用及其调控.中国骨质疏松杂志,1997；3(4)：80-81
[7]马文松,刘磊,朱小弟等.骨质疏松血清IL-6与骨代谢生化指标的变化.中国骨质疏松杂志,2002；8(4)：327-328
[8]熊学华,冯新送.原发性骨质疏松症病因及发病机理研究进展.中国中医骨伤科杂志,2000；8(4)：49-50
[9]Passeri G, Girasole G, Jilka RL, et al. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology,1993;133:822-823
[10]张安国,刘小朋,陈紫榕,等.白细胞介素6、雌激素与绝经后骨质疏松症关系的研究.标记免疫分析与临床,1999；6(2)：65-67
[1]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget,s disease.N Engl J Med,2002;347:1622-1623.
[2]曾晓峰.骨代谢与免疫功能的相互调节.细胞与分子免疫学杂志,2003；19(6)：629-632
[3]Kostenuik PJ,Shalhoub V.Osteoprotegerin:a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des,2001; 7(8): 613-635
[4]Wong BR,Rho J,Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor famlily that activates c-Jun N-terminal kinase in T cells. J Biol Chem,1997;272:25190-25194
[5]李娟,唐井钢,吴贺勇,等.雌二醇与雷洛昔芬对体外培养成骨细胞生物学功能的影响及护骨素表达的调控.第一军医大学学报,2005；25(7)：787-790.
[6]Li X,Pilbeam CC,Pan l,et al.Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.Bone,2002;30(4):567-573
[7]周振雷,陶庆树,胡丹,等.细胞因子对骨代谢的调节.中国骨质疏松杂志,2006；12(1)：73-75
[8]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget,s disease.N Engl J Med,2002;347:1622-1623.
[9]Hamdy N A. Targeting the RANK/RANKL/OPG singnaling pathway:a novel approach in the management of osteoporosis. Curropin Investig Drugs,2007;8(4):299-303
[1]Jilka RL.Cytokines,bone remodeling,and estrogen deficiency:a 1998 update.Bone,1998;23:75-81.
[2]Handy N A.Targeting the RANK/RANKL/OPG signaling pathway a novel approach in the management of osteoporosis.Curr Op in Investing Drugs,2007;8(4):299-303
[3]Russel RG,Espina B,Hulley p,rt al.Bone biology and the pathogenesis. Curr-Opin-Rheumatol,2006; 18(Supplel):3-10
[4]Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem BiophysResCommun,2001;280(3):831-835
[5]白孟海,葛宝丰,白洁,等.去势大鼠骨髓体外培养破骨细胞观察及 OPGmRNA表达的变化.中国骨质疏松杂志,2009；15(4)：272-274
[6]梁少俊,刘宏,杨力,等.绝经后骨质疏松与血清OPG及RANKL关系的研究.广东医学,2006；27(5)：669-671
[7]郭梁.成骨细胞、破骨细胞及OPG/RANKL/RANK轴与骨质疏松症.中医正骨,2010；22(7)：41-44
[8]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget,s disease.N Engl J Med,2002;347(3):175-184.
[9]Rogers A, Saleh G, Hannon RA, et al.Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.J Clin Endocrinol Metab,2002;87:4470-4475
[10]刘建民,赵红燕,宁光,等.20-75岁妇女血清护骨素、核因子κB受体活化子配体的变化与年龄、停经、骨生化指标和骨密度的关系.中华内科杂志,2004；43(6)：447-450
[11]Browner WS,Lui LY,Cummings SR.Associations of serum osteoprotegerin levels with diabetes,stroke,bone density,fractures,and mortality in elderly women.J Clin Endocrinol Metab 2001,86:631-637
[12]商敏.OPG/RANKL/RANK系统与绝经后骨质疏松症.中国骨质疏松杂志,2008；14(7)：532-535
[13]贾少杰,贾晓静.雌激素抗骨质疏松的OPG/RANKL和A poE作用机制的实验研究.中国老年学杂志,2007；27(12)：2274-2276
[14]涂平生,徐杰.护骨素的研究进展.解剖学研究,2004；26(4)：301-304
[15]Yoshitake F, Itoh S, Narita H, et al. Intedeukin-6 direetly inhibits osteoelast differentiation by suppressing receptor activator of NF-kappaB signaling pathways.J Biol Chem,2008;283(17):11535-11540
[16]王晓庚,刘文佳,周洪,等.不同浓度破骨细胞分化因子和巨噬细胞集落刺激因子体外诱导大鼠破骨样细胞形成的研究.口腔医学,2008；28(40)：169-172
[17]杨健,谭颖徽,裘松波.核因子κB受体活化因子配体诱导大鼠骨髓破骨 细胞形成的实验研究.重庆医学,2004；33(3)：385-388
[18]高延征,高坤,钟楚楠,等.RANKL、OPG在去卵巢大鼠骨组织中蛋白表达动态变化.医药论坛杂志,2009；30(5)：4-6
[1]张华,冯新送,庄洪等.中医对原发性骨质疏松症的认识及辨证施治研究.中医正骨,2001；13(3)：55.
[2]冯世纶.骨质疏松症的中医病名刍议.中国骨质疏松杂志,2001；(7)：91
[3]程栋.龙攀.周海艇等.中医药治疗骨质疏松症研究近况.中国骨质疏松杂志,2003；9(1)：86
[4]丁桂芝.从骨矿含量变化规律看肾主骨理论的科学性.中医杂志,1991；13(2)：27
[5]赵玉堂,李金花,许灿.从骨钙含量与肾虚的关系探讨肾主骨的本质.前卫医药杂志,1994；11(2)：118-119
[6]许志奇,郭素华,杨定焯,等.肾虚症矿物质含量的初步研究.中西医结合杂志,1991；11(3)：221
[7]舒俊.补肾益精方加减治疗骨质疏松症50例疗效观察.职业卫生与病伤,2005；20(2)：143-144
[8]黄海,成羿,朱杭,等.补肾中药防治去睾大鼠骨丢失的组织学机理研究.浙江中医学院学报,2001；25(1)：52-54
[9]郭郡浩,张永文,赵智明,等.补肾抗松丸对绝经后骨质疏松症患者骨密度的影响.安徽中医学院学报,2008；27(5)：14-15
[10]徐亚莉,金建军,徐登玉,等.针刺加穴位贴敷对原发性骨质疏松症患者骨密度及疼痛的影响.中国针灸,2006；26(2)：87-90
[11]王彦春,吴昌清,宋照祥,等,针刺大鼠肾俞穴对尿量的影响.湖北中医学院学报,2000；2(4)：14-16
[12]吴中朝,王玲玲,徐兰风.艾灸对老年人血浆睾酮、雌二醇的影响.中国针灸,1998；18(8)：27-28
[13]梁伟春,李笔锋,黄志敬.以《内经》理论探讨骨质疏松症的预防.光明中医,2010；25(3)：358-360
[14]王翔,赵咏芳,石印玉,等.健脾方对去势大鼠维生素D代谢的影响.中国骨质疏松杂志,2007；13(6)：429-432
[15]欧阳钢,王玲玲,王东岩,等.针刺对绝经后妇女骨密度的影响.中医杂志,2001；42(2)：88-89
[16]杜莹,吴宗霈,邵敏.血瘀与绝经后骨质疏松症的关系.中医正骨,2006；18(80：79-80
[17]田牛,李玉珍,刘育英.血瘀证的微循环研究.中国中西医结合杂志,2001；21(4)：248-251
[18]湖波.肾虚血瘀与绝经后骨质疏松症的发病述要.内蒙古中医药,2006；25(2)：38-39
[19]谢林,郭振球,姚共和.绝经后骨质疏松症中医辨证分析.中国医药学报,1999；14(3)：35-39
[20]姚新苗.益骨汤合药血清对成骨细胞增殖和ALP影响.浙江中医药大学学报,2007；31(2)：158.
[21]胡年宏.补肾健脾活血法防治骨质疏松症的研究概况.中医正骨,2004；16(5)：53
[22]眭承志,周军.从瘀论治绝经后骨质疏松症的理论探析.中医药学刊,2005；23(1)：92-94
[23]马界.针刺对去卵巢大鼠骨质疏松症骨代谢及血清雌二醇含量的影响.针刺研究,2008；33(4)：235-239
[24]莫晓枫,梁若茄.腹针治疗原发性骨质疏松症的临床观察,中国中医药科技,2007；14(5)：315
[25]郭盛君,夏东胜,郭志强.82例绝经后妇女骨质疏松程度与中医证型的关系.中国医学研究与临床,2005；3(9)：32-33
[26]赵利华,农泽宁,钟旋,等.温针灸对绝经后骨质疏松症患者骨密度及生化指标的影响.中国针灸,2008；28(12)：897-900
[27]黄杰文,秦佳佳,张素萍.中药骨康对骨质疏松模型大鼠骨密度的影响.广州中医药大学学报,2009；26(6)：546-548
[28]张敏,何树梅,章晓凤,等.健脾补肾活血法治疗老年性骨质疏松的研究.陕西中医,2009；30(2)：244-246
[29]王华,梁凤霞.“双固一通”针灸法与疾病防治.湖北中医杂志,2004；26(4)：3-5
[30]胡玲,汪惠丽,高忻洙,等.电针“关元”与“三阴交”对围绝经期模型大鼠性激素及下丘脑p-EP调整作用的比较.中国针灸,2004；24(9)：649-651
[31]江瑜,桑海滨,张和媛.张氏腹三针对卵巢早衰大鼠卵巢内分泌功能影响的实验研究.贵阳中医学院学报,2009；31(2)：59-62
[32]刘晓艳,吕明.针刺雄性小鼠关元穴对性腺激素影响的实验研究.南京中医药大学学报,2010；26(5)：383-384
[33]王维,李荣亨.针灸关元、气海穴对气虚证小鼠耐疲劳能力与免疫指标的影响.中国中医急症,2008；17(10)：1433-1444
[34]周金山,晋志高,陶之理.一级感觉神经元在脊神经节的节段分布.上海针灸杂志,2001；20(3)：40-41
[35]何国栋,牛伟新,刘寒,等.电针足三里穴对兔胃肠道平滑肌电活动的影响及与胃动素、胆囊收缩素关系的研究.中国临床医学,2007；14(4)：504-506
[36]唐省三.“针必取三里,灸必加关元”浅见.山东中医杂志,2002；21(4)：245-246
[37]贾育松.穴位注射治疗绝经后骨质疏松症初探.中国骨质疏松杂志,2003；9(23)：171-149
[38]崔瑾,申定珠,熊芳丽.针灸膈俞对白细胞共同抗原及免疫功能的影响.四川中医,2006,24(2)：100-102
[39]杨廉,刘嫒媛,路暾,等.温针灸“肾俞”穴对老年雌性大鼠性激素的影响.中国针灸,2001；21(3)：172-173
[40]熊芳丽,肖亚平,姬锋养.针灸大杼、膈俞、肾俞及断端局部穴位促进骨折愈合疗效观察.四川中医,2005；23(11)：100-101
[41]王华,洪亚群,曾晓玲,等.“双固一通”法对老年实验性急性心肌缺血模 型大鼠心电图的影响.上海针灸杂志,2003；22(9)：11-13
[42]吴松,唐宏图,陈泽斌,等.“双固一通”法对老年实验性急性心肌缺血模型大鼠心肌组织过氧化物酶活性的影响.湖北中医学院针灸骨伤学院建院25周年庆典,湖北省暨武汉针灸学会针推、骨伤学术大会论文汇编：138-139
[43]周晓莉,刘品莉,姜青松,等.“双固一通”针法治疗绝经后骨质疏松症的临床研究.中国骨质疏松杂志,2008；14(3)：204-207
[44]周晓莉,鲍圣涌,王华“双固一通”针法治疗绝经后骨质疏松症的临床研究.医学综述杂志,2007；13(23)：1852-1854
[45]戴如春.张丽,廖二元.骨质疏松症的诊治进展.中国医刊,2008；43(4)：4-6
[46]黄武,刘幼硕.老年骨质疏松症的诊断与治疗要点.中华老年医学杂志,2005；24(12)：939-941
[47]李仲廉.原发性骨质疏松症的诊疗.中国疼痛医学杂志,2006；12(1)：40-43
[48]王颜刚,王桂兰,王伟.白细胞介素6在老年原发性骨质疏松症发病中的作用.中国骨质疏松杂志,1996；2(2)：75-78
[49]秦岭,张戈(译).美国国家卫生院有关骨质疏松症的预防、诊断和治疗的共识文件.中国骨质疏松杂志,2002；8(1)：90-93
[50]柴生廷,庄洪,魏合伟.骨质疏松性骨折流行病学研究进展.中医正骨,2004；16(2)：55-56
[51]朴俊红,庞莲萍,刘忠厚,等.中国人口状况及原发性骨质疏松症诊断标准和发生率.中国骨质疏松杂志,2002；8(1)：1-7
[52]朱国英,王洪复,王伟华,等.绝经后骨质疏松症的发生率与诊断标准研究.中华实用医学,2002；4(17)：1-4
[53]林芸,陈党生.骨密度测量部位对女性骨质疏松症诊断的影响.中国现代实用医学杂志,2004；3(15)：9-11
[54]唐海,李永刚,陈浩.骨密度测量技术的临床应用及评价.实用糖尿病杂志,2006；2(4)：9-11
[55]周久贸,刘浩,蒋森,等.沈阳地区2288例骨密度测定及骨质疏松症发病率分析.中国临床医学影像杂志,2008；19(2)：121-124
[56]Hawler GA,Jamal SA,Ridout R,et al.A clinical prediction rule to identify premenopausal women with low bone mass.Osteoporos Int,2002; 13:400-406
[57]崔轶,雷伟,吴子祥,等.骨质疏松大动物模型的研究进展.脊柱外科杂志,2010；8(5)：316-320
[58]王晓,梅其炳,刘莉,等.骨质疏松动物模型的复制与评价.中国骨质疏松杂志,2007；13(2)：141-145
[59]沈辉,潘时中.大鼠切除卵巢骨质疏松模型的实验研究.福建医科大学学报,2004；38(2)：152-154
[60]D. D. Thompson, H. A. Simmons, C. M. Pirie, et al. FDA guidelines and animal models for osteoporosis.Bone,1995;17(10):25
[61]Kavuncu V, Sahin S, Baydas G, et al. A comparison of estrogen and two different doses of calcitonin in ovariectomized rats. Yonsei Med J, 2003;44(3):508-516
[62]萨仁,王富春,池岛乔.针灸治疗实验性骨质疏松症对肿瘤坏死因子基因表达的影响.针刺研究,2004；29(2)：140-144
[63]张洪,崔德芝,陈韶坤.补肾坚骨胶囊对去势大鼠骨代谢指标的影响.浙江中西医结合杂志,2004；14(12)：729-730
[64]黄洪,田成功.邦得林治疗雄性骨质疏松大鼠的实验研究.南京医科大学学报,2001；21(1)：47
[65]Peng ZQ,Vaananen HK,Zhang HX,et al. Long-term effects of ovariectomy on the mechanical properties and chemical composition of rat bone. Bone 1997;20(3):207-212
[66]袁勇,钟卫军.骨质疏松症的动物实验研究进展.湖南中医药导报,2003；9(12)：50-51
[67]郭宏,张润荃,刘洪臣,等.去势大鼠骨质疏松模型的综合评定.中华老年 口腔医学杂志,2009；7(4)：196-234
[68]Rogers A, Eastell RA, Eastell R.Biochemical makers as predictors of rats of bone loss after menopause. J Bone Miner Res,2000;15(7):1398-1404
[69]王萍玉,张亨菊.骨质疏松症的膳食危险因素研究进展.卫生研究,2003；32(1)：81-83
[70]刘庆利,权铁刚,唐广志,等.中药治疗对去卵巢大鼠骨质疏松动物模型血钙、血磷、碱性磷酸酶与骨密度的影响.中国老年学杂志,2008；28(15)：1527-1528
[71]熊学华,冯新送.原发性骨质疏松症病因及发病机理研究进展.中国中医骨伤科杂志,2000；8(4)：49-50.
[72]刘忠厚.骨质疏松症.北京：科学出版社,1998,第一版：67-78
[73]薛延.骨质疏松症诊断与治疗指南,北京：科学出版社,1999,第一版：217
[74]安胜军,杨学辉,李恩.雌激素与骨质疏松症.中国骨质疏松杂志,1999；5(3)：81-82
[75]王智兴,李群.成骨生长肽对成骨细胞样细胞的成骨影响.中华骨科杂志,2000；20(1)：58-60
[76]卓铁军,周一明,刘俊恒,等.骨质疏松患者骨密度和几种骨代谢参数的关系.实用老年医学,1998；12(4)：163
[77]莫新民,曾英,洪净.去卵巢雌鼠骨质疏松模型的生化特点.中国中医基础学杂志,1999；5(12)：17
[78]刘忠厚.骨质疏松学,北京：科学技术出版,1998,1：218.
[79]陈名道.美国停止对健康绝经期后妇女激素替代治疗的临床试验.国外医学内分泌学分册,2002；22(5)：34
[80]Hasegawa J, Nagashima M, Yamamoto M, et al. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritias. J Rheumatol,2003;30(3):474-479
[81]Weaver CM, Peacock M, Martin BR, et al. Immunoassay for quantifying type Ⅰ collagen degradation products in urine evaluated. Clin Chem,1994;40:2022-25
[82]Price PA, Williamson MK, Lothringer JW. Origin of the Vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem,1981,256(24):12760-12766
[83]Auschka PV, Lian JB, Cole DEC, et al. Osteocalcin and matrix Gla Protein; vitamin K-dependent proteins in bone. Physiol Rev,1989;69: 990-1047
[84]黄江渝,胡汶竹.血清骨钙素水平检测的临床应用现状.现代预防医学,2007；34(9)：1674-1675
[85]章明放,黄凤歧,谭郁彬,等.去势大鼠血清骨钙素水平及意义.中国骨质疏松杂志,1999；5(03)：22-24
[86]杨伟民,邵斌.骨代谢生化指标与骨质疏松症.中国骨质疏松杂志,2004,10(10)：118-121
[87]冯莉,杨静华,李熙明,等.尿脱氧吡啶啉用于绝经前子宫切除妇女骨代谢变化检测的研究.中国骨质疏松杂志,2007,13(11)：791-793
[88]马文松,刘磊,朱小弟等.骨质疏松血清IL-6与骨代谢生化指标的变化.中国骨质疏松杂志,2002,8(4)：327-328.
[89]刘忠厚.骨质疏松症.北京：科学出版社,1998,第一版：179
[90]庞勇,赵利华,农泽宁,等.针灸治疗原发性骨质疏松症临床研究.上海针灸杂志,2008；27(12)：144-147
[91]何国栋,牛伟新,刘寒,等.电针足三里穴对兔胃肠道平滑肌电活动的影响及与胃动素、胆囊收缩素关系的研究.中国临床医学,2007；14(4)：504-506
[92]肖少卿.浅谈足三里养生保健的意义与应用.江苏中医,1998；19(7)：35
[93]许咏乐.雌激素受体与绝经后骨质疏松.国外医学妇产科分册,2005；32(4)：274-277
[94]安胜军,杨学辉,李恩.雌激素与骨质疏松症.中国骨质疏松杂志,1999；5(3)：81-82
[95]齐绍霞.小剂量雌激素预防围绝经期骨质疏松症的临床观察.中国骨质疏松杂志,2008；14(7)：517-49
[96]Shevde NK, Pike JW. Estrogen modulates the recruitment of muelopoietic cell progenitors in rat thrugh a strimal cell-independent mechanism involving apoptosis. Blood,1996; 87:2683-2693
[97]Jilka RL.Cytokines,bone remodeling,and estrogen deficiency:a 1998 update.Bone,1998;23:75-81.
[98]童安莉,陈璐璐.白细胞介素6在骨吸收中的作用及其调控.中国骨质疏松杂志,1997；3(4)：80-81
[99]马文松,刘磊,朱小弟等.骨质疏松血清IL-6与骨代谢生化指标的变化.中国骨质疏松杂志,2002；8(4)：327-328.
[100]Passeri G, Girasole Q Jilka RL, et al. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology,1993;133:822-823
[101]张安国,刘小朋,陈紫榕,等.白细胞介素6、雌激素与绝经后骨质疏松症关系的研究.标记免疫分析与临床,1999；6(2)：65-67.
[102]Burgess TL,Kaufiana S,et al.The ligand for osteoprotgerin (OPGL) directly activates mature osteoclasts. J Cell Biol,1999;145:527-538
[103]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget,s disease.N Engl J Med,2002;347(3):175-184.
[104]Ong YY, Feige U,etal. Activated Tcells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature,1999;402:304。
[105]曾晓峰.骨代谢与免疫功能的相互调节.细胞与分子免疫学杂志,2003,19(6)：629-632
[106]Kostenuik PJ,Shalhoub V.Osteoprotegerin:a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des,2001; 7(8):613-635
[107]Wong BR,Rho J,Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor famlily that activates c-Jun N-terminal kinase in T cells. J Biol Chem,1997;272:25190-25194
[108]李娟,唐井钢,吴贺勇,等.雌二醇与雷洛昔芬对体外培养成骨细胞生物学功能的影响及护骨素表达的调控.第一军医大学学报,2005；25(7)：787-790
[109]Li X,Pilbeam CC,Pan l,et al.Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.Bone,2002; (4):567-573
[110]周振雷,陶庆树,胡丹,等.细胞因子对骨代谢的调节.中国骨质疏松杂志,2006；12(1)：73-75
[111]Hamdy N A. Targeting the RANK/RANKL/OPG singnaling pathway:a novel approach in the management of osteoporosis. Curropin Investig Drugs,2007;8(4):299-303
[112]Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun,2001;280(3):831-835
[113]白孟海,葛宝丰,白洁,等.去势大鼠骨髓体外培养破骨细胞观察及OPGmRNA表达的变化.中国骨质疏松杂志,2009；15(4)：272-274
[114]梁少俊,刘宏,杨力,等.绝经后骨质疏松与血清OPG及RANKL关系的研究.广东医学,2006；27(5)：669-671
[115]郭梁.成骨细胞、破骨细胞及OPG/RANKL/RANK轴与骨质疏松症.中医正骨,2010,22(7)：41-44
[116]Rogers A, Saleh G, Hannon RA, et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab,2002; 87:4470-4475
[117]刘建民,赵红燕,宁光,等.20-75岁妇女血清护骨素、核因子κB受体活化子配体的变化与年龄、停经、骨生化指标和骨密度的关系.中华内 科杂志,2004；43(6)：447-450
[118]Browner WS, Lui LY, Cummings SR.Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.J Clin Endocrinol Metab,2001;86:631-637
[119]商敏.OPG/RANKL/RANK系统与绝经后骨质疏松症.中国骨质疏松杂志,2008；14(7)：532-535
[120]贾少杰,贾晓静.雌激素抗骨质疏松的OPG/RANKL和A poE作用机制的实验研究.中国老年学杂志,2007；27(12)：2274-2276
[121]涂平生,徐杰.护骨素的研究进展.解剖学研究,2004；26(4)：301-304
[122]Yoshitake F, Itoh S, Narita H, et al. Intedeukin-6 direetly inhibits osteoelast differentiation by suppressing receptor activator of NF-kappaB signaling pathways.J Biol Chem,2008;283(17):11535-11540.
[123]王晓庚,刘文佳,周洪,等.不同浓度破骨细胞分化因子和巨噬细胞集落刺激因子体外诱导大鼠破骨样细胞形成的研究.口腔医学,2008；28(40：169-172
[124]杨健,谭颖徽,裘松波.核因子κB受体活化因子配体诱导大鼠骨髓破骨细胞形成的实验研究.重庆医学,2004；33(3)：385-388
[125]高延征,高坤,钟楚楠,等.RANKL、OPG在去卵巢大鼠骨组织中蛋白表达动态变化.医药论坛杂志,2009；30(5)：4-6
[1]张华,冯新送,庄洪等.中医对原发性骨质疏松症的认识及辨证施治研究.中医正骨,2001；13(3)：55
[2]冯世纶.骨质疏松症的中医病名刍议.中国骨质疏松杂志,2001；(7)：91
[3]马界.针刺对去卵巢大鼠骨质疏松症骨代谢及血清雌二醇含量的影响.针刺研究,2008；33(4)：235-239
[4]吴成长.骨质疏松针灸辨治探析.现代中西医结合杂志,2004；13(1)：77-78
[5]赵利华,农泽宁,钟旋,等.温针灸对绝经后骨质疏松症患者骨密度及生化指标的影响.中国针灸,2008；28(12)：897-900
[6]欧阳钢,王玲玲,王东岩,等.针刺对绝经后妇女骨密度的影响.中医杂志,2001；42(2)：88-89
[7]周丕琪,沈霖,杜靖远等.补肾法对绝经后骨质疏松患者I1-6、TNF-α的影响.中国中医骨伤科杂志,2000；8(4)：1-3
[8]刘炎,王维健.针灸补肾健脾法治疗骨质疏松症的临床观察.针灸临床杂志,1996；12(7.8)：24-25
[9]贾育松.穴位注射治疗绝经后骨质疏松症初探.中国骨质疏松杂志,2003；9(23)：171-149
[10]王东岩,蔡红,卓铁军.针刺背部腧穴对骨质疏松症腰椎骨密度的影响.湖北中医杂志,2001；23(2)：6
[11]吴明霞,吴炳煌,刘献祥等.艾灸对绝经后骨质疏松症影响的实验和临床研究.中国针灸,2002；22(5)：324-326
[12]刘献祥,吴明霞,吴炳煌,等.针灸对原发性骨质疏松症影响的实验和临床研究.中国骨伤,2000；13(9)：519-521
[13]金肖青,文晓林,于澎,等.电针治疗原发性骨质疏松症临床32例分析.中医药学刊,2003；21(4)：70-71
[14]吴志明.骨质疏松症腰背痛的临床体会.中国中医骨伤科杂志,1999；7(2)：23-24
[15]齐振熙.辨证治疗绝经后骨质疏松症.中国中医骨伤科杂志,1998；6(3)：28-29
[16]许书亮,张永宝.骨质疏松症的辨证分型与治疗.中国中医骨伤科杂志,1995；3(4)：30-31
[17]陈维静,刘新梅,廉红其.中医辨证治疗原发性骨质疏松症(附109例报道).中医药报道,1999；15(3)：30-31
[18]刘广霞.针灸督脉为主治疗老年性骨质疏松症28例临床报道.中国针灸,2000；20(9)：529
[19]曹飞.腰椎骨质疏松症治阴为本治阳为标..新中医,1994；(12)：32
[20]林莺,许金榜.针灸治疗绝经后骨质疏松症临床研究思路.中医药学刊,2006；24(1)：177-179
[21]周德祥,王东岩.骨质疏松症的针灸治疗概况及述评.针灸临床杂志,2000；16(1)：54-55
[22]陈友国.悬灸为主治疗绝经后骨质疏松症疗效观察.上海针灸杂志,2010；29(6)：407
[23]赵利华,农泽宁,钟旋,等.温针灸对绝经后骨质疏松症患者骨密度及生化指标的影响.中国针灸,2008,28(12)：897-900
[24]潘文宇,李艳慧.针刺加火针治疗绝经后骨质疏松56例.中医药学刊,2003；21(5)：811-812
[25]林莺,许金榜,李沛.针药结合对绝经后妇女骨代谢调节作用的临床研究.福建医药杂志,2009；31(6)：131-133
[26]罗小珍,罗盛华.灸配合蜡疗治疗骨质疏松症腰背痛的临床研究.广西中医药,2009；32(6)：42-44
[27]贾育松.穴位注射治疗绝经后骨质疏松症初探.中国骨质疏 松,2003；9(2)：171
[28]林志苇,黎健,高丽萍,等.肾俞穴位埋线对绝经后骨质疏松症临床疼痛的疗效观察.针灸临床杂志,2004；20(12)：7-8
[29]艾双春,路雪婧,廖方正.神阙穴贴药对原发性骨质疏松症超声穿透速度的影响.中国针灸,2003；23(1)：17-19
[30]王东岩,王玲玲,欧阳钢等.红外灸疗仪治疗对原发性骨质疏松症骨密度的影响.国医论坛,2000；15(6)：23
[31]蔡红.不同治疗频次对原发性骨质疏松症骨密度的影响.中国针灸,2003；23(1)：15-16
[32]Maras I.电针治疗自发性骨质疏松症.国外医学中医分册,1996；18(2)：51
[33]张丽.隔药灸调节老年骨密度的研究.中医函授通讯,1997；16(1)：35
[34]李晶,王艳,李平.针灸对去势大鼠骨代谢影响的生化研究.天津中医药,2008；25(1)：26-28
[35]王华,鲍圣涌,周晓莉.“双固一通”针法对绝经后骨质疏松症模型大鼠骨矿物质含量、骨密度和雌二醇的影响.上海针灸杂志,2005；24(10)：39-41
[36]鲍圣涌,王华,王彦春,等.“双固一通”针法对绝经后骨质疏松症模型大鼠骨保护蛋白mRNA表达水平的影响.针刺研究,2006；31(3)：149-152
[37]鲍圣涌,王华,阎德文,等.“双固一通”针法对绝经后骨质疏松症模型大鼠胰岛素样生长因子及组织形态学的影响.中国骨质疏松杂志,2008；14(9)：619-623
[38]王长海,田立民,冯文,等.针刺对绝经后骨质疏松症骨密度及血液流变性的影响.中国中医急症,2004；13(5)：284-285
[1]王颜刚,王桂兰,王伟.白细胞介素6在老年原发性骨质疏松症发病中的作用.中国骨质疏松杂志,1996；2(2)：75-78
[2]Ralston.Genetic control of susceptibility to osteoporosis. J Clin Endo Metab,2002;87:2460-2466.
[3]Ong YY, Feige U,etal. Activated Tcells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 1999;402:304
[4]Laeey DL,Timms E,Tan HL,et al.Osteoprotegerin ligand is a cytokine that regulates osteoclast diferentiation and activation.Cell,1998;93:3597-3602
[5]Yasuda H,Shim N,Nakagawa N,et al.Identity of osteoclastogenesis inhibitory factor(OCIF) and osteoprotegerin(OPG):a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.Endocrinology, 1998;139:1329-1337
[6]Hsu H, Lacey D L, Dunstan C R, et aL.Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.Proc Nad Aead Sci USA,1999;96 (7),3540-3545.
[7]曾晓峰.骨代谢与免疫功能的相互调节.细胞与分子免疫学杂志,2003；19(6)：629-632
[8]Kostenuik PJ,Shalhoub V.Osteoprotegerin:a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des,2001; 7(8):613-635
[9]Li X,Pilbeam CC,Pan l,et al.Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.Bone,2002;30(4):567-573
[10]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget,s disease.N Engl J Med,2002;347(3):175-184
[11]Wong BRJ,Rho j,Arron j, et al.TRANCE is a novel ligand of the tumor necrosis factor receptor famlily that activates c-jun N-terminal kinase in T cell. J Biol Chem,1997;272:25190-25194
[12]Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun,2001;280(3):831-835
[13]白孟海,葛宝丰,白洁,等.去势大鼠骨髓体外培养破骨细胞观察及 OPGmRNA表达的变化.中国骨质疏松杂志,2009；15(4)：272-274
[14]高延征,高坤,沈彬,等.去卵巢后大鼠骨组织中核因子κB受体活化因子配体和骨保护素表达的变化.中国组织工程研究与临床康复,2009；13(15)：2877-2881
[15]武兆忠,刘敏,冯鉴强.RNA干扰抑制雌激素受体α亚基对雌激素诱导人成骨样细胞护骨素表达的影响.中国老年学杂志.2005；25(2)：179-182
[16]苏欣,廖二元,朱旭萍,等.雌二醇对人成骨细胞护骨素、护骨素配体及其相关因子的调节.中华老年医学杂志,2004；23(3)：153-156
[17]贾少杰,贾晓静.雌激素抗骨质疏松的OPG(?)和A poE作用机制的实验研究.中国老年学杂志,2007；27(12)：2274-2276
[18]李娟,唐井钢,吴贺勇,等.雌二醇与雷洛昔芬对体外培养成骨细胞生物学功能的影响及护骨素表达的调控.第一军医大学学报,2005；25(7)：787-790
[19]涂平生,徐杰.护骨素的研究进展.解剖学研究.2004；26(4)：301-304
[20]Itoh S,Udagawa N,Takahashi N,et ai.A criticsl role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation.Bone,2006;39(3):505-512
[21]Yoshitake F, Itoh S, Narita H, et al. Intedeukin-6 direetly inhibits osteoelast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem,2008;283(17):11535-11540
[22]Blanchard F, Duplomb L.Baud'huin M, et al. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev,2009;20(1):19-28.
[23]梁少俊,刘宏,杨力,等.绝经后骨质疏松与血清OPG及RANKL关系的研究.广东医学,2006；27(5)：669-671
[24]Rogers A,Saleh QHannon RA,et al.Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.J Clin Endocrinol Metab,2002;87:4470-4475.
[25]郭梁.成骨细胞、破骨细胞及OPG/RANKL/RANK轴与骨质疏松症.中医正骨,2010；22(7)：41-44
[26]刘建民,赵红燕,宁光,等.20-75岁妇女血清护骨素、核因子κB受体活化子配体的变化与年龄、停经、骨生化指标和骨密度的关系.中华内科杂志,2004；43(6)：447-450
[27]Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab,2001;86:631-637
[28]商敏.OPG/RANKL/RANK系统与绝经后骨质疏松症.中国骨质疏松杂志,2008；14(7)：532-535
[29]贾少杰,贾晓静.雌激素抗骨质疏松的OPG和A poE作用机制的实验研究.中国老年学杂志,2007；27(12)：2274-2276
[30]涂平生,徐杰.护骨素的研究进展.解剖学研究,2004；26(4)：301-304
[31]王晓庚,刘文佳,周洪,等.不同浓度破骨细胞分化因子和巨噬细胞集落刺激因子体外诱导大鼠破骨样细胞形成的研究.口腔医学,2008；28(40)：169-172
[32]杨健,谭颖徽,裘松波.核因子KB受体活化因子配体诱导大鼠骨髓破骨细胞形成的实验研究.重庆医学,2004；33(3)：385-388
[33]Jilka RL.Cytokines,bone remodeling,and estrogen deficiency:a 1998 update.Bone,1998;23(2):75-81
[34]Russel RG,Espina B,Hulley p,rt al.Bone biology and the pathogenesis. Curr-Opin-Rheumatol,2006; 18(Supplel):3-10
[35]Handy N A.Targeting the RANK/RANKL/OPG signaling pathway a novel approach in the management of osteoporosis. Curr Op in Investing Drugs,2007;8(4):299-303
[2]李恩.原发性骨质疏松发病的相关因素.中国骨质疏松杂志,1997；3(2)：1-2
[3]刘忠厚.骨质疏松学.北京：科学技术出版社.1998,第1版：929
[4]李瑛,邹季,任捷.退行性骨质疏松症诊断.中外健康文摘：医药月刊,2008；5(2)：93-94
[5]刘忠厚主编.骨矿与临床.北京：科学技术出版社.2006,第1版：7
[6]Li X,Pilbeam CC,Pan l,et al.Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.Bone,2002;30(4):567-573
[7]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget's disease.N Engl J Med,2002;347(3):175-184
[8]曾晓峰.骨代谢与免疫功能的相互调节.细胞与分子免疫学杂志,2003；19(6)：629-632
[9]武兆忠,刘敏,冯鉴强.RNA干扰抑制雌激素受体α亚基对雌激素诱导人成骨样细胞护骨素表达的影响.中国老年学杂志,2005；25(2)：179-182
[10]Jilka RL.Cytokines,bone remodeling,and estrogen deficiency:a 1998 update.Bone,1998;23:75-81
[11]Writing group for the women's health initiative investigations.Risks and benefits of estrogestin in healthy Postmenopausal women:principal results from the women's health initiative randomized controlled trial. JAMA,2002;288(3):321-333
[12]陈名道.美国停止对健康绝经期后妇女激素替代治疗的临床试验.国外医学内分泌学分册,2002；22(5)：34
[13]金肖青,文晓林,于澎,等.电针治疗原发性骨质疏松症临床32例分析.中医药学刊,2003；21(4)：70-71
[14]刘献祥,吴明霞,吴炳煌,等.针灸对原发性骨质疏松症影响的实验和临床研究.中国骨伤,2000；13(9)：519-521
[15]张华,冯新送,庄洪等.中医对原发性骨质疏松症的认识及辨证施治研究.中医正骨,2001；13(3)：55
[16]周晓莉,鲍圣涌,王华.“双固一通”针灸疗法对绝经后骨质疏松症骨密度的影响.湖北中医杂志,2005；27(6)：49-50
[17]周晓莉,鲍圣涌,王华.“双固一通”针法治疗绝经后骨质疏松症的临床研究.医学综述杂志,2007；13(23)：1852-1854.
[18]周晓莉,刘品莉,姜青松,等.“双固一通”针法治疗绝经后骨质疏松症的临床研究.中国骨质疏松杂志,2008；14(3)：204-207.
[19]周晓莉.”双固一通”针法对绝经后骨质疏松症患者的临床研究.湖北中医学院硕士毕业论文.2005
[20]鲍圣涌,王华,周晓莉.“双固一通”针法治疗绝经后骨质疏松症模型大鼠BMC、BMD及E2的影响.上海针灸杂志,2005；24(11)：28
[21]鲍圣涌,王华,王彦春,等.”双固一通”针法对绝经后骨质疏松症模型大鼠骨组织骨保护蛋白mRNA表达水平的影响.针刺研究,2006；31(3)：
[22]鲍圣涌,王华,阎德文,等.”双固一通”针法对绝经后骨质疏松症模型大鼠胰岛素样生长因子-1及组织形态学的影响.中国骨质疏松杂志,2008；14(9)：619-623
[23]黄永南.“双固一通”针法对绝经后骨质疏松症模型大鼠的骨密度、免疫球蛋白及RANKLm RNA表达水平的影响.湖北中医学院硕士毕业论文.2008
[1]华兴邦,李辞蓉,周浩良,等.大鼠穴位图谱的研制.实验动物与动物实验,1991；1：1-5
[2]林文注主编.实验针灸学.上海：上海科学技术出版社,1999,第一版：288-290
[3]孙敬方.动物实验方法学.北京：人民卫生出版社,2011,第一版：357
[4]Mul lender MG, Van der Meer DD, and Huiskes R, et al. Osteocyte density changes in aging and osteoporosis. Bone,1996; 18,109
[5]Rogers A, Eastell RA, Eastell R.Biochemical makers as predictors of rats of bone loss after menopause. J Bone Miner Res,2000;15(7):1398-1404
[6]王萍玉,张亨菊.骨质疏松症的膳食危险因素研究进展.卫生研究,2003；32(1)：81-83
[7]刘忠厚.骨质疏松症.北京：科学出版社,1998,第一版：67-78
[8]薛延等.骨质疏松症诊断与治疗指南.北京：科学出版社,1999,第一版：217
[9]安胜军,杨学辉,李恩.雌激素与骨质疏松症.中国骨质疏松杂志,1999；5(3)：81-82
[10]王智兴,李群.成骨生长肽对成骨细胞样细胞的成骨影响.中华骨科杂志,2000；20(1)：58-60
[11]周晓莉,刘品莉,姜青松,等.“双固一通”针法治疗绝经后骨质疏松症的临床研究.中国骨质疏松杂志,2008；14(3)：204-207
[12]Hasegawa J, Nagashima M, Yamamoto M, et al. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritias. J Rheumatol,2003;30(3):474-479
[13]Weaver CM, Peacock M, Martin BR, et al. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem,1994; 40:2022-25
[14]Price PA, Williamson MK, Lothringer JW. Origin of the Vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem,1981;256(24):12760-12766
[15]Auschka PV, Lian JB, Cole DEC, et al. Osteocalcin and matrix Gla Protein; vitamin K-dependent proteins in bone. Physiol Rev,1989;69: 990-1047
[16]黄江渝,胡汶竹.血清骨钙素水平检测的临床应用现状.现代预防医学,2007；34(9)：1674-1675
[17]冯莉,杨静华,李熙明,等.尿脱氧吡啶啉用于绝经前子宫切除妇女骨代谢变化检测的研究.中国骨质疏松杂志,2007；13(11)：791-793
[18]马文松,刘磊,朱小弟等.骨质疏松血清IL-6与骨代谢生化指标的变化.中国骨质疏松杂志,2002；8(4)：327-328
[19]刘忠厚.骨质疏松症.北京：科学出版社,1998,第一版：179
[20]庞勇,赵利华,农泽宁,等.针灸治疗原发性骨质疏松症临床研究.上海针灸杂志,2008；27(12)：144-147
[21]何国栋,牛伟新,刘寒,等.电针足三里穴对兔胃肠道平滑肌电活动的影响及与胃动素、胆囊收缩素关系的研究.中国临床医学,2007；14(4)：504-506
[22]肖少卿.浅谈足三里养生保健的意义与应用.江苏中医,1998；19(7)：35
[23]贾育松.穴位注射治疗绝经后骨质疏松症初探.中国骨质疏松杂志,2003；9(23)：171-149
[1]秦岭,张戈(译).美国国家卫生院有关骨质疏松症的预防、诊断和治疗的共识文件.中国骨质疏松杂志.2002；8(1)：90-93
[2]柴生廷,庄洪,魏合伟.骨质疏松性骨折流行病学研究进展.中医正骨,2004；16(2)：55-56
[3]朴俊红,庞莲萍,刘忠厚,等.中国人口状况及原发性骨质疏松症诊断标准和发生率.中国骨质疏松杂志,2002；8(1)：1-7
[4]朱国英,王洪复,王伟华,等.绝经后骨质疏松症的发生率与诊断标准研究.中华实用医学杂志,2002；4(17)：1-4
[5]林芸,陈党生.骨密度测量部位对女性骨质疏松症诊断的影响.中国现代实用医学杂志,2004；3(15)：9-11
[6]唐海,李永刚,陈浩.骨密度测量技术的临床应用及评价.实用糖尿病杂志,2006；2(4)：9-11
[7]周久贸,刘浩,蒋森,等.沈阳地区2288例骨密度测定及骨质疏松症发病率分析.中国临床医学影像杂志,2008；19(2)：121-124
[8]Hawler GA,Jamal SA,Ridout R,et al.A clinical prediction rule to identify premenopausal women with low bone mass.Osteoporos Int.2002;13:400-406
[9]周晓莉,鲍圣涌,王华.“双固一通”针法治疗绝经后骨质疏松症的临床研究.医学综述,2007；13(23)：1852-1854
[1]崔轶,雷伟,吴子祥,等.骨质疏松大动物模型的研究进展.脊柱外科杂志,2010；8(5)：316-320
[2]王晓,梅其炳,刘莉,等.骨质疏松动物模型的复制与评价.中国骨质疏松杂志,2007；13(2)：141-145
[3]沈辉,潘时中.大鼠切除卵巢骨质疏松模型的实验研究.福建医科大学学报,2004；38(2)：152-154
[4]D. D. Thompson, H. A. Simmons, C. M. Pirie, et al. FDA guidelines and animal models for osteoporosis.Bone,1995; 17(10):25
[5]Kavuncu V, Sahin S, Baydas G, et al. A comparison of estrogen and two different doses of calcitonin in ovariectomized rats. Yonsei Med J, 2003;44(3):508-516
[6]萨仁,王富春,池岛乔.针灸治疗实验性骨质疏松症对肿瘤坏死因子基因 表达的影响.针刺研究,2004；29(2)：140-144
[7]张洪,崔德芝,陈韶坤.补肾坚骨胶囊对去势大鼠骨代谢指标的影响.浙江中西医结合杂志,2004；14(12)：729-730
[8]黄洪,田成功.邦得林治疗雄性骨质疏松大鼠的实验研究.南京医科大学,2001；21(1)：47
[9]武密山,赵素芝,李恩.抗骨松穴位贴剂对骨质疏松大鼠模型作用机理研究.上海中医药大学学报,2001；15(1)：45
[10]周丽,邓伟民,韩丽萍.补肾壮骨颗粒对维甲酸致骨质疏松大鼠骨组织计量学的影响.实验动物科学,2009；26(3)：7-10
[11]乔伟伟,许兰文,杨幼明,等.大鼠营养干预性骨质疏松症模型的研究.上海实验动物科学,2002；22(3)：145-151
[12]李晓康,周涛,王志彬,等.针刺对损毁弓状核大鼠所致骨质疏松症的干预研究.天津中医药,2007；24(5)：380-382
[13]洪志勇,刘爱平.制作骨质疏松症大鼠模型的甲状旁腺切除法.上海实验动物科学,1996；16(2)：85-86
[14]Masse PG, Boskey AL, Ziv I, et al. Chemical and biomechanical characterization of hyperhomocysteinemic bone disease in an animal model. BMC Musculoskelet Disord,2003;4(1):2
[15]郑成杰,李洪洋,潭建三.骨磷抗去坐骨神经雄鼠骨质疏松实验研究.右江民族医学院学报,1999；21(4)：547
[16]唐学阳,刘利君,彭明惺,等.腿-尾固定法建立大鼠废用性骨质疏松模型.中国临床康复,2003；7(15)：2131-2134
[17]Rodgers JB,Monier-Faugere MC,Malluche H. Animal models for the study of bone loss after cessation of ovarian function. Bone 1993; 14(3): 369-377
[18]Kalu DN. The ovariectomized rat model of postmenopausal bone loss.Bone Miner 1991;15(3):175-191·
[19]Peng ZQ,Vaananen HK,Zhang HX,et al. Long-term effects of ovariectomy on the mechanical properties and chemical composition of rat bone. Bone,1997;20(3):207-212
[20]袁勇,钟卫军.骨质疏松症的动物实验研究进展.湖南中医药导报,2003；9(12)：50-51
[21]Wronski T J,Citron M,Danm L M.Temporal relationship between bone loss and increased bone turnover in ovariectomized rats.Calcif Tissue Int,1988,42:179
[22]郭宏,张润荃,刘洪臣,等.去势大鼠骨质疏松模型的综合评定.中华老年口腔医学杂志,2009；7(4)：196-234
[1]许咏乐.雌激素受体与绝经后骨质疏松.国外医学妇产科分册,2005；32(4)：274-277
[2]安胜军,杨学辉,李恩.雌激素与骨质疏松症.中国骨质疏松杂志,1999；5(3)：81-82
[3]齐绍霞.小剂量雌激素预防围绝经期骨质疏松症的临床观察.中国骨质疏松杂志,2008；14(7)：517-49
[4]Shevde NK, Pike JW. Estrogen moduiates the recruitment of muelopoietic cell progenitors in rat thrugh a strimal cell-independent mechanism involving apoptosis. Blood,1996; 87:2683-2693
[5]Jilka RL.Cytokines,bone remodeling,and estrogen deficiency:a 1998 update.Bone,1998;23:75-81
[6]童安莉,陈璐璐.白细胞介素6在骨吸收中的作用及其调控.中国骨质疏松杂志,1997；3(4)：80-81
[7]马文松,刘磊,朱小弟等.骨质疏松血清IL-6与骨代谢生化指标的变化.中国骨质疏松杂志,2002；8(4)：327-328
[8]熊学华,冯新送.原发性骨质疏松症病因及发病机理研究进展.中国中医骨伤科杂志,2000；8(4)：49-50
[9]Passeri G, Girasole G, Jilka RL, et al. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology,1993;133:822-823
[10]张安国,刘小朋,陈紫榕,等.白细胞介素6、雌激素与绝经后骨质疏松症关系的研究.标记免疫分析与临床,1999；6(2)：65-67
[1]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget,s disease.N Engl J Med,2002;347:1622-1623.
[2]曾晓峰.骨代谢与免疫功能的相互调节.细胞与分子免疫学杂志,2003；19(6)：629-632
[3]Kostenuik PJ,Shalhoub V.Osteoprotegerin:a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des,2001; 7(8): 613-635
[4]Wong BR,Rho J,Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor famlily that activates c-Jun N-terminal kinase in T cells. J Biol Chem,1997;272:25190-25194
[5]李娟,唐井钢,吴贺勇,等.雌二醇与雷洛昔芬对体外培养成骨细胞生物学功能的影响及护骨素表达的调控.第一军医大学学报,2005；25(7)：787-790.
[6]Li X,Pilbeam CC,Pan l,et al.Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.Bone,2002;30(4):567-573
[7]周振雷,陶庆树,胡丹,等.细胞因子对骨代谢的调节.中国骨质疏松杂志,2006；12(1)：73-75
[8]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget,s disease.N Engl J Med,2002;347:1622-1623.
[9]Hamdy N A. Targeting the RANK/RANKL/OPG singnaling pathway:a novel approach in the management of osteoporosis. Curropin Investig Drugs,2007;8(4):299-303
[1]Jilka RL.Cytokines,bone remodeling,and estrogen deficiency:a 1998 update.Bone,1998;23:75-81.
[2]Handy N A.Targeting the RANK/RANKL/OPG signaling pathway a novel approach in the management of osteoporosis.Curr Op in Investing Drugs,2007;8(4):299-303
[3]Russel RG,Espina B,Hulley p,rt al.Bone biology and the pathogenesis. Curr-Opin-Rheumatol,2006; 18(Supplel):3-10
[4]Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem BiophysResCommun,2001;280(3):831-835
[5]白孟海,葛宝丰,白洁,等.去势大鼠骨髓体外培养破骨细胞观察及 OPGmRNA表达的变化.中国骨质疏松杂志,2009；15(4)：272-274
[6]梁少俊,刘宏,杨力,等.绝经后骨质疏松与血清OPG及RANKL关系的研究.广东医学,2006；27(5)：669-671
[7]郭梁.成骨细胞、破骨细胞及OPG/RANKL/RANK轴与骨质疏松症.中医正骨,2010；22(7)：41-44
[8]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget,s disease.N Engl J Med,2002;347(3):175-184.
[9]Rogers A, Saleh G, Hannon RA, et al.Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.J Clin Endocrinol Metab,2002;87:4470-4475
[10]刘建民,赵红燕,宁光,等.20-75岁妇女血清护骨素、核因子κB受体活化子配体的变化与年龄、停经、骨生化指标和骨密度的关系.中华内科杂志,2004；43(6)：447-450
[11]Browner WS,Lui LY,Cummings SR.Associations of serum osteoprotegerin levels with diabetes,stroke,bone density,fractures,and mortality in elderly women.J Clin Endocrinol Metab 2001,86:631-637
[12]商敏.OPG/RANKL/RANK系统与绝经后骨质疏松症.中国骨质疏松杂志,2008；14(7)：532-535
[13]贾少杰,贾晓静.雌激素抗骨质疏松的OPG/RANKL和A poE作用机制的实验研究.中国老年学杂志,2007；27(12)：2274-2276
[14]涂平生,徐杰.护骨素的研究进展.解剖学研究,2004；26(4)：301-304
[15]Yoshitake F, Itoh S, Narita H, et al. Intedeukin-6 direetly inhibits osteoelast differentiation by suppressing receptor activator of NF-kappaB signaling pathways.J Biol Chem,2008;283(17):11535-11540
[16]王晓庚,刘文佳,周洪,等.不同浓度破骨细胞分化因子和巨噬细胞集落刺激因子体外诱导大鼠破骨样细胞形成的研究.口腔医学,2008；28(40)：169-172
[17]杨健,谭颖徽,裘松波.核因子κB受体活化因子配体诱导大鼠骨髓破骨 细胞形成的实验研究.重庆医学,2004；33(3)：385-388
[18]高延征,高坤,钟楚楠,等.RANKL、OPG在去卵巢大鼠骨组织中蛋白表达动态变化.医药论坛杂志,2009；30(5)：4-6
[1]张华,冯新送,庄洪等.中医对原发性骨质疏松症的认识及辨证施治研究.中医正骨,2001；13(3)：55.
[2]冯世纶.骨质疏松症的中医病名刍议.中国骨质疏松杂志,2001；(7)：91
[3]程栋.龙攀.周海艇等.中医药治疗骨质疏松症研究近况.中国骨质疏松杂志,2003；9(1)：86
[4]丁桂芝.从骨矿含量变化规律看肾主骨理论的科学性.中医杂志,1991；13(2)：27
[5]赵玉堂,李金花,许灿.从骨钙含量与肾虚的关系探讨肾主骨的本质.前卫医药杂志,1994；11(2)：118-119
[6]许志奇,郭素华,杨定焯,等.肾虚症矿物质含量的初步研究.中西医结合杂志,1991；11(3)：221
[7]舒俊.补肾益精方加减治疗骨质疏松症50例疗效观察.职业卫生与病伤,2005；20(2)：143-144
[8]黄海,成羿,朱杭,等.补肾中药防治去睾大鼠骨丢失的组织学机理研究.浙江中医学院学报,2001；25(1)：52-54
[9]郭郡浩,张永文,赵智明,等.补肾抗松丸对绝经后骨质疏松症患者骨密度的影响.安徽中医学院学报,2008；27(5)：14-15
[10]徐亚莉,金建军,徐登玉,等.针刺加穴位贴敷对原发性骨质疏松症患者骨密度及疼痛的影响.中国针灸,2006；26(2)：87-90
[11]王彦春,吴昌清,宋照祥,等,针刺大鼠肾俞穴对尿量的影响.湖北中医学院学报,2000；2(4)：14-16
[12]吴中朝,王玲玲,徐兰风.艾灸对老年人血浆睾酮、雌二醇的影响.中国针灸,1998；18(8)：27-28
[13]梁伟春,李笔锋,黄志敬.以《内经》理论探讨骨质疏松症的预防.光明中医,2010；25(3)：358-360
[14]王翔,赵咏芳,石印玉,等.健脾方对去势大鼠维生素D代谢的影响.中国骨质疏松杂志,2007；13(6)：429-432
[15]欧阳钢,王玲玲,王东岩,等.针刺对绝经后妇女骨密度的影响.中医杂志,2001；42(2)：88-89
[16]杜莹,吴宗霈,邵敏.血瘀与绝经后骨质疏松症的关系.中医正骨,2006；18(80：79-80
[17]田牛,李玉珍,刘育英.血瘀证的微循环研究.中国中西医结合杂志,2001；21(4)：248-251
[18]湖波.肾虚血瘀与绝经后骨质疏松症的发病述要.内蒙古中医药,2006；25(2)：38-39
[19]谢林,郭振球,姚共和.绝经后骨质疏松症中医辨证分析.中国医药学报,1999；14(3)：35-39
[20]姚新苗.益骨汤合药血清对成骨细胞增殖和ALP影响.浙江中医药大学学报,2007；31(2)：158.
[21]胡年宏.补肾健脾活血法防治骨质疏松症的研究概况.中医正骨,2004；16(5)：53
[22]眭承志,周军.从瘀论治绝经后骨质疏松症的理论探析.中医药学刊,2005；23(1)：92-94
[23]马界.针刺对去卵巢大鼠骨质疏松症骨代谢及血清雌二醇含量的影响.针刺研究,2008；33(4)：235-239
[24]莫晓枫,梁若茄.腹针治疗原发性骨质疏松症的临床观察,中国中医药科技,2007；14(5)：315
[25]郭盛君,夏东胜,郭志强.82例绝经后妇女骨质疏松程度与中医证型的关系.中国医学研究与临床,2005；3(9)：32-33
[26]赵利华,农泽宁,钟旋,等.温针灸对绝经后骨质疏松症患者骨密度及生化指标的影响.中国针灸,2008；28(12)：897-900
[27]黄杰文,秦佳佳,张素萍.中药骨康对骨质疏松模型大鼠骨密度的影响.广州中医药大学学报,2009；26(6)：546-548
[28]张敏,何树梅,章晓凤,等.健脾补肾活血法治疗老年性骨质疏松的研究.陕西中医,2009；30(2)：244-246
[29]王华,梁凤霞.“双固一通”针灸法与疾病防治.湖北中医杂志,2004；26(4)：3-5
[30]胡玲,汪惠丽,高忻洙,等.电针“关元”与“三阴交”对围绝经期模型大鼠性激素及下丘脑p-EP调整作用的比较.中国针灸,2004；24(9)：649-651
[31]江瑜,桑海滨,张和媛.张氏腹三针对卵巢早衰大鼠卵巢内分泌功能影响的实验研究.贵阳中医学院学报,2009；31(2)：59-62
[32]刘晓艳,吕明.针刺雄性小鼠关元穴对性腺激素影响的实验研究.南京中医药大学学报,2010；26(5)：383-384
[33]王维,李荣亨.针灸关元、气海穴对气虚证小鼠耐疲劳能力与免疫指标的影响.中国中医急症,2008；17(10)：1433-1444
[34]周金山,晋志高,陶之理.一级感觉神经元在脊神经节的节段分布.上海针灸杂志,2001；20(3)：40-41
[35]何国栋,牛伟新,刘寒,等.电针足三里穴对兔胃肠道平滑肌电活动的影响及与胃动素、胆囊收缩素关系的研究.中国临床医学,2007；14(4)：504-506
[36]唐省三.“针必取三里,灸必加关元”浅见.山东中医杂志,2002；21(4)：245-246
[37]贾育松.穴位注射治疗绝经后骨质疏松症初探.中国骨质疏松杂志,2003；9(23)：171-149
[38]崔瑾,申定珠,熊芳丽.针灸膈俞对白细胞共同抗原及免疫功能的影响.四川中医,2006,24(2)：100-102
[39]杨廉,刘嫒媛,路暾,等.温针灸“肾俞”穴对老年雌性大鼠性激素的影响.中国针灸,2001；21(3)：172-173
[40]熊芳丽,肖亚平,姬锋养.针灸大杼、膈俞、肾俞及断端局部穴位促进骨折愈合疗效观察.四川中医,2005；23(11)：100-101
[41]王华,洪亚群,曾晓玲,等.“双固一通”法对老年实验性急性心肌缺血模 型大鼠心电图的影响.上海针灸杂志,2003；22(9)：11-13
[42]吴松,唐宏图,陈泽斌,等.“双固一通”法对老年实验性急性心肌缺血模型大鼠心肌组织过氧化物酶活性的影响.湖北中医学院针灸骨伤学院建院25周年庆典,湖北省暨武汉针灸学会针推、骨伤学术大会论文汇编：138-139
[43]周晓莉,刘品莉,姜青松,等.“双固一通”针法治疗绝经后骨质疏松症的临床研究.中国骨质疏松杂志,2008；14(3)：204-207
[44]周晓莉,鲍圣涌,王华“双固一通”针法治疗绝经后骨质疏松症的临床研究.医学综述杂志,2007；13(23)：1852-1854
[45]戴如春.张丽,廖二元.骨质疏松症的诊治进展.中国医刊,2008；43(4)：4-6
[46]黄武,刘幼硕.老年骨质疏松症的诊断与治疗要点.中华老年医学杂志,2005；24(12)：939-941
[47]李仲廉.原发性骨质疏松症的诊疗.中国疼痛医学杂志,2006；12(1)：40-43
[48]王颜刚,王桂兰,王伟.白细胞介素6在老年原发性骨质疏松症发病中的作用.中国骨质疏松杂志,1996；2(2)：75-78
[49]秦岭,张戈(译).美国国家卫生院有关骨质疏松症的预防、诊断和治疗的共识文件.中国骨质疏松杂志,2002；8(1)：90-93
[50]柴生廷,庄洪,魏合伟.骨质疏松性骨折流行病学研究进展.中医正骨,2004；16(2)：55-56
[51]朴俊红,庞莲萍,刘忠厚,等.中国人口状况及原发性骨质疏松症诊断标准和发生率.中国骨质疏松杂志,2002；8(1)：1-7
[52]朱国英,王洪复,王伟华,等.绝经后骨质疏松症的发生率与诊断标准研究.中华实用医学,2002；4(17)：1-4
[53]林芸,陈党生.骨密度测量部位对女性骨质疏松症诊断的影响.中国现代实用医学杂志,2004；3(15)：9-11
[54]唐海,李永刚,陈浩.骨密度测量技术的临床应用及评价.实用糖尿病杂志,2006；2(4)：9-11
[55]周久贸,刘浩,蒋森,等.沈阳地区2288例骨密度测定及骨质疏松症发病率分析.中国临床医学影像杂志,2008；19(2)：121-124
[56]Hawler GA,Jamal SA,Ridout R,et al.A clinical prediction rule to identify premenopausal women with low bone mass.Osteoporos Int,2002; 13:400-406
[57]崔轶,雷伟,吴子祥,等.骨质疏松大动物模型的研究进展.脊柱外科杂志,2010；8(5)：316-320
[58]王晓,梅其炳,刘莉,等.骨质疏松动物模型的复制与评价.中国骨质疏松杂志,2007；13(2)：141-145
[59]沈辉,潘时中.大鼠切除卵巢骨质疏松模型的实验研究.福建医科大学学报,2004；38(2)：152-154
[60]D. D. Thompson, H. A. Simmons, C. M. Pirie, et al. FDA guidelines and animal models for osteoporosis.Bone,1995;17(10):25
[61]Kavuncu V, Sahin S, Baydas G, et al. A comparison of estrogen and two different doses of calcitonin in ovariectomized rats. Yonsei Med J, 2003;44(3):508-516
[62]萨仁,王富春,池岛乔.针灸治疗实验性骨质疏松症对肿瘤坏死因子基因表达的影响.针刺研究,2004；29(2)：140-144
[63]张洪,崔德芝,陈韶坤.补肾坚骨胶囊对去势大鼠骨代谢指标的影响.浙江中西医结合杂志,2004；14(12)：729-730
[64]黄洪,田成功.邦得林治疗雄性骨质疏松大鼠的实验研究.南京医科大学学报,2001；21(1)：47
[65]Peng ZQ,Vaananen HK,Zhang HX,et al. Long-term effects of ovariectomy on the mechanical properties and chemical composition of rat bone. Bone 1997;20(3):207-212
[66]袁勇,钟卫军.骨质疏松症的动物实验研究进展.湖南中医药导报,2003；9(12)：50-51
[67]郭宏,张润荃,刘洪臣,等.去势大鼠骨质疏松模型的综合评定.中华老年 口腔医学杂志,2009；7(4)：196-234
[68]Rogers A, Eastell RA, Eastell R.Biochemical makers as predictors of rats of bone loss after menopause. J Bone Miner Res,2000;15(7):1398-1404
[69]王萍玉,张亨菊.骨质疏松症的膳食危险因素研究进展.卫生研究,2003；32(1)：81-83
[70]刘庆利,权铁刚,唐广志,等.中药治疗对去卵巢大鼠骨质疏松动物模型血钙、血磷、碱性磷酸酶与骨密度的影响.中国老年学杂志,2008；28(15)：1527-1528
[71]熊学华,冯新送.原发性骨质疏松症病因及发病机理研究进展.中国中医骨伤科杂志,2000；8(4)：49-50.
[72]刘忠厚.骨质疏松症.北京：科学出版社,1998,第一版：67-78
[73]薛延.骨质疏松症诊断与治疗指南,北京：科学出版社,1999,第一版：217
[74]安胜军,杨学辉,李恩.雌激素与骨质疏松症.中国骨质疏松杂志,1999；5(3)：81-82
[75]王智兴,李群.成骨生长肽对成骨细胞样细胞的成骨影响.中华骨科杂志,2000；20(1)：58-60
[76]卓铁军,周一明,刘俊恒,等.骨质疏松患者骨密度和几种骨代谢参数的关系.实用老年医学,1998；12(4)：163
[77]莫新民,曾英,洪净.去卵巢雌鼠骨质疏松模型的生化特点.中国中医基础学杂志,1999；5(12)：17
[78]刘忠厚.骨质疏松学,北京：科学技术出版,1998,1：218.
[79]陈名道.美国停止对健康绝经期后妇女激素替代治疗的临床试验.国外医学内分泌学分册,2002；22(5)：34
[80]Hasegawa J, Nagashima M, Yamamoto M, et al. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritias. J Rheumatol,2003;30(3):474-479
[81]Weaver CM, Peacock M, Martin BR, et al. Immunoassay for quantifying type Ⅰ collagen degradation products in urine evaluated. Clin Chem,1994;40:2022-25
[82]Price PA, Williamson MK, Lothringer JW. Origin of the Vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem,1981,256(24):12760-12766
[83]Auschka PV, Lian JB, Cole DEC, et al. Osteocalcin and matrix Gla Protein; vitamin K-dependent proteins in bone. Physiol Rev,1989;69: 990-1047
[84]黄江渝,胡汶竹.血清骨钙素水平检测的临床应用现状.现代预防医学,2007；34(9)：1674-1675
[85]章明放,黄凤歧,谭郁彬,等.去势大鼠血清骨钙素水平及意义.中国骨质疏松杂志,1999；5(03)：22-24
[86]杨伟民,邵斌.骨代谢生化指标与骨质疏松症.中国骨质疏松杂志,2004,10(10)：118-121
[87]冯莉,杨静华,李熙明,等.尿脱氧吡啶啉用于绝经前子宫切除妇女骨代谢变化检测的研究.中国骨质疏松杂志,2007,13(11)：791-793
[88]马文松,刘磊,朱小弟等.骨质疏松血清IL-6与骨代谢生化指标的变化.中国骨质疏松杂志,2002,8(4)：327-328.
[89]刘忠厚.骨质疏松症.北京：科学出版社,1998,第一版：179
[90]庞勇,赵利华,农泽宁,等.针灸治疗原发性骨质疏松症临床研究.上海针灸杂志,2008；27(12)：144-147
[91]何国栋,牛伟新,刘寒,等.电针足三里穴对兔胃肠道平滑肌电活动的影响及与胃动素、胆囊收缩素关系的研究.中国临床医学,2007；14(4)：504-506
[92]肖少卿.浅谈足三里养生保健的意义与应用.江苏中医,1998；19(7)：35
[93]许咏乐.雌激素受体与绝经后骨质疏松.国外医学妇产科分册,2005；32(4)：274-277
[94]安胜军,杨学辉,李恩.雌激素与骨质疏松症.中国骨质疏松杂志,1999；5(3)：81-82
[95]齐绍霞.小剂量雌激素预防围绝经期骨质疏松症的临床观察.中国骨质疏松杂志,2008；14(7)：517-49
[96]Shevde NK, Pike JW. Estrogen modulates the recruitment of muelopoietic cell progenitors in rat thrugh a strimal cell-independent mechanism involving apoptosis. Blood,1996; 87:2683-2693
[97]Jilka RL.Cytokines,bone remodeling,and estrogen deficiency:a 1998 update.Bone,1998;23:75-81.
[98]童安莉,陈璐璐.白细胞介素6在骨吸收中的作用及其调控.中国骨质疏松杂志,1997；3(4)：80-81
[99]马文松,刘磊,朱小弟等.骨质疏松血清IL-6与骨代谢生化指标的变化.中国骨质疏松杂志,2002；8(4)：327-328.
[100]Passeri G, Girasole Q Jilka RL, et al. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology,1993;133:822-823
[101]张安国,刘小朋,陈紫榕,等.白细胞介素6、雌激素与绝经后骨质疏松症关系的研究.标记免疫分析与临床,1999；6(2)：65-67.
[102]Burgess TL,Kaufiana S,et al.The ligand for osteoprotgerin (OPGL) directly activates mature osteoclasts. J Cell Biol,1999;145:527-538
[103]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget,s disease.N Engl J Med,2002;347(3):175-184.
[104]Ong YY, Feige U,etal. Activated Tcells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature,1999;402:304。
[105]曾晓峰.骨代谢与免疫功能的相互调节.细胞与分子免疫学杂志,2003,19(6)：629-632
[106]Kostenuik PJ,Shalhoub V.Osteoprotegerin:a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des,2001; 7(8):613-635
[107]Wong BR,Rho J,Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor famlily that activates c-Jun N-terminal kinase in T cells. J Biol Chem,1997;272:25190-25194
[108]李娟,唐井钢,吴贺勇,等.雌二醇与雷洛昔芬对体外培养成骨细胞生物学功能的影响及护骨素表达的调控.第一军医大学学报,2005；25(7)：787-790
[109]Li X,Pilbeam CC,Pan l,et al.Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.Bone,2002; (4):567-573
[110]周振雷,陶庆树,胡丹,等.细胞因子对骨代谢的调节.中国骨质疏松杂志,2006；12(1)：73-75
[111]Hamdy N A. Targeting the RANK/RANKL/OPG singnaling pathway:a novel approach in the management of osteoporosis. Curropin Investig Drugs,2007;8(4):299-303
[112]Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun,2001;280(3):831-835
[113]白孟海,葛宝丰,白洁,等.去势大鼠骨髓体外培养破骨细胞观察及OPGmRNA表达的变化.中国骨质疏松杂志,2009；15(4)：272-274
[114]梁少俊,刘宏,杨力,等.绝经后骨质疏松与血清OPG及RANKL关系的研究.广东医学,2006；27(5)：669-671
[115]郭梁.成骨细胞、破骨细胞及OPG/RANKL/RANK轴与骨质疏松症.中医正骨,2010,22(7)：41-44
[116]Rogers A, Saleh G, Hannon RA, et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab,2002; 87:4470-4475
[117]刘建民,赵红燕,宁光,等.20-75岁妇女血清护骨素、核因子κB受体活化子配体的变化与年龄、停经、骨生化指标和骨密度的关系.中华内 科杂志,2004；43(6)：447-450
[118]Browner WS, Lui LY, Cummings SR.Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.J Clin Endocrinol Metab,2001;86:631-637
[119]商敏.OPG/RANKL/RANK系统与绝经后骨质疏松症.中国骨质疏松杂志,2008；14(7)：532-535
[120]贾少杰,贾晓静.雌激素抗骨质疏松的OPG/RANKL和A poE作用机制的实验研究.中国老年学杂志,2007；27(12)：2274-2276
[121]涂平生,徐杰.护骨素的研究进展.解剖学研究,2004；26(4)：301-304
[122]Yoshitake F, Itoh S, Narita H, et al. Intedeukin-6 direetly inhibits osteoelast differentiation by suppressing receptor activator of NF-kappaB signaling pathways.J Biol Chem,2008;283(17):11535-11540.
[123]王晓庚,刘文佳,周洪,等.不同浓度破骨细胞分化因子和巨噬细胞集落刺激因子体外诱导大鼠破骨样细胞形成的研究.口腔医学,2008；28(40：169-172
[124]杨健,谭颖徽,裘松波.核因子κB受体活化因子配体诱导大鼠骨髓破骨细胞形成的实验研究.重庆医学,2004；33(3)：385-388
[125]高延征,高坤,钟楚楠,等.RANKL、OPG在去卵巢大鼠骨组织中蛋白表达动态变化.医药论坛杂志,2009；30(5)：4-6
[1]张华,冯新送,庄洪等.中医对原发性骨质疏松症的认识及辨证施治研究.中医正骨,2001；13(3)：55
[2]冯世纶.骨质疏松症的中医病名刍议.中国骨质疏松杂志,2001；(7)：91
[3]马界.针刺对去卵巢大鼠骨质疏松症骨代谢及血清雌二醇含量的影响.针刺研究,2008；33(4)：235-239
[4]吴成长.骨质疏松针灸辨治探析.现代中西医结合杂志,2004；13(1)：77-78
[5]赵利华,农泽宁,钟旋,等.温针灸对绝经后骨质疏松症患者骨密度及生化指标的影响.中国针灸,2008；28(12)：897-900
[6]欧阳钢,王玲玲,王东岩,等.针刺对绝经后妇女骨密度的影响.中医杂志,2001；42(2)：88-89
[7]周丕琪,沈霖,杜靖远等.补肾法对绝经后骨质疏松患者I1-6、TNF-α的影响.中国中医骨伤科杂志,2000；8(4)：1-3
[8]刘炎,王维健.针灸补肾健脾法治疗骨质疏松症的临床观察.针灸临床杂志,1996；12(7.8)：24-25
[9]贾育松.穴位注射治疗绝经后骨质疏松症初探.中国骨质疏松杂志,2003；9(23)：171-149
[10]王东岩,蔡红,卓铁军.针刺背部腧穴对骨质疏松症腰椎骨密度的影响.湖北中医杂志,2001；23(2)：6
[11]吴明霞,吴炳煌,刘献祥等.艾灸对绝经后骨质疏松症影响的实验和临床研究.中国针灸,2002；22(5)：324-326
[12]刘献祥,吴明霞,吴炳煌,等.针灸对原发性骨质疏松症影响的实验和临床研究.中国骨伤,2000；13(9)：519-521
[13]金肖青,文晓林,于澎,等.电针治疗原发性骨质疏松症临床32例分析.中医药学刊,2003；21(4)：70-71
[14]吴志明.骨质疏松症腰背痛的临床体会.中国中医骨伤科杂志,1999；7(2)：23-24
[15]齐振熙.辨证治疗绝经后骨质疏松症.中国中医骨伤科杂志,1998；6(3)：28-29
[16]许书亮,张永宝.骨质疏松症的辨证分型与治疗.中国中医骨伤科杂志,1995；3(4)：30-31
[17]陈维静,刘新梅,廉红其.中医辨证治疗原发性骨质疏松症(附109例报道).中医药报道,1999；15(3)：30-31
[18]刘广霞.针灸督脉为主治疗老年性骨质疏松症28例临床报道.中国针灸,2000；20(9)：529
[19]曹飞.腰椎骨质疏松症治阴为本治阳为标..新中医,1994；(12)：32
[20]林莺,许金榜.针灸治疗绝经后骨质疏松症临床研究思路.中医药学刊,2006；24(1)：177-179
[21]周德祥,王东岩.骨质疏松症的针灸治疗概况及述评.针灸临床杂志,2000；16(1)：54-55
[22]陈友国.悬灸为主治疗绝经后骨质疏松症疗效观察.上海针灸杂志,2010；29(6)：407
[23]赵利华,农泽宁,钟旋,等.温针灸对绝经后骨质疏松症患者骨密度及生化指标的影响.中国针灸,2008,28(12)：897-900
[24]潘文宇,李艳慧.针刺加火针治疗绝经后骨质疏松56例.中医药学刊,2003；21(5)：811-812
[25]林莺,许金榜,李沛.针药结合对绝经后妇女骨代谢调节作用的临床研究.福建医药杂志,2009；31(6)：131-133
[26]罗小珍,罗盛华.灸配合蜡疗治疗骨质疏松症腰背痛的临床研究.广西中医药,2009；32(6)：42-44
[27]贾育松.穴位注射治疗绝经后骨质疏松症初探.中国骨质疏 松,2003；9(2)：171
[28]林志苇,黎健,高丽萍,等.肾俞穴位埋线对绝经后骨质疏松症临床疼痛的疗效观察.针灸临床杂志,2004；20(12)：7-8
[29]艾双春,路雪婧,廖方正.神阙穴贴药对原发性骨质疏松症超声穿透速度的影响.中国针灸,2003；23(1)：17-19
[30]王东岩,王玲玲,欧阳钢等.红外灸疗仪治疗对原发性骨质疏松症骨密度的影响.国医论坛,2000；15(6)：23
[31]蔡红.不同治疗频次对原发性骨质疏松症骨密度的影响.中国针灸,2003；23(1)：15-16
[32]Maras I.电针治疗自发性骨质疏松症.国外医学中医分册,1996；18(2)：51
[33]张丽.隔药灸调节老年骨密度的研究.中医函授通讯,1997；16(1)：35
[34]李晶,王艳,李平.针灸对去势大鼠骨代谢影响的生化研究.天津中医药,2008；25(1)：26-28
[35]王华,鲍圣涌,周晓莉.“双固一通”针法对绝经后骨质疏松症模型大鼠骨矿物质含量、骨密度和雌二醇的影响.上海针灸杂志,2005；24(10)：39-41
[36]鲍圣涌,王华,王彦春,等.“双固一通”针法对绝经后骨质疏松症模型大鼠骨保护蛋白mRNA表达水平的影响.针刺研究,2006；31(3)：149-152
[37]鲍圣涌,王华,阎德文,等.“双固一通”针法对绝经后骨质疏松症模型大鼠胰岛素样生长因子及组织形态学的影响.中国骨质疏松杂志,2008；14(9)：619-623
[38]王长海,田立民,冯文,等.针刺对绝经后骨质疏松症骨密度及血液流变性的影响.中国中医急症,2004；13(5)：284-285
[1]王颜刚,王桂兰,王伟.白细胞介素6在老年原发性骨质疏松症发病中的作用.中国骨质疏松杂志,1996；2(2)：75-78
[2]Ralston.Genetic control of susceptibility to osteoporosis. J Clin Endo Metab,2002;87:2460-2466.
[3]Ong YY, Feige U,etal. Activated Tcells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 1999;402:304
[4]Laeey DL,Timms E,Tan HL,et al.Osteoprotegerin ligand is a cytokine that regulates osteoclast diferentiation and activation.Cell,1998;93:3597-3602
[5]Yasuda H,Shim N,Nakagawa N,et al.Identity of osteoclastogenesis inhibitory factor(OCIF) and osteoprotegerin(OPG):a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.Endocrinology, 1998;139:1329-1337
[6]Hsu H, Lacey D L, Dunstan C R, et aL.Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.Proc Nad Aead Sci USA,1999;96 (7),3540-3545.
[7]曾晓峰.骨代谢与免疫功能的相互调节.细胞与分子免疫学杂志,2003；19(6)：629-632
[8]Kostenuik PJ,Shalhoub V.Osteoprotegerin:a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des,2001; 7(8):613-635
[9]Li X,Pilbeam CC,Pan l,et al.Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.Bone,2002;30(4):567-573
[10]Hofbauer LC,Schoppet M. Osteoprotegerin deficiency and juvenile paget,s disease.N Engl J Med,2002;347(3):175-184
[11]Wong BRJ,Rho j,Arron j, et al.TRANCE is a novel ligand of the tumor necrosis factor receptor famlily that activates c-jun N-terminal kinase in T cell. J Biol Chem,1997;272:25190-25194
[12]Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun,2001;280(3):831-835
[13]白孟海,葛宝丰,白洁,等.去势大鼠骨髓体外培养破骨细胞观察及 OPGmRNA表达的变化.中国骨质疏松杂志,2009；15(4)：272-274
[14]高延征,高坤,沈彬,等.去卵巢后大鼠骨组织中核因子κB受体活化因子配体和骨保护素表达的变化.中国组织工程研究与临床康复,2009；13(15)：2877-2881
[15]武兆忠,刘敏,冯鉴强.RNA干扰抑制雌激素受体α亚基对雌激素诱导人成骨样细胞护骨素表达的影响.中国老年学杂志.2005；25(2)：179-182
[16]苏欣,廖二元,朱旭萍,等.雌二醇对人成骨细胞护骨素、护骨素配体及其相关因子的调节.中华老年医学杂志,2004；23(3)：153-156
[17]贾少杰,贾晓静.雌激素抗骨质疏松的OPG(?)和A poE作用机制的实验研究.中国老年学杂志,2007；27(12)：2274-2276
[18]李娟,唐井钢,吴贺勇,等.雌二醇与雷洛昔芬对体外培养成骨细胞生物学功能的影响及护骨素表达的调控.第一军医大学学报,2005；25(7)：787-790
[19]涂平生,徐杰.护骨素的研究进展.解剖学研究.2004；26(4)：301-304
[20]Itoh S,Udagawa N,Takahashi N,et ai.A criticsl role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation.Bone,2006;39(3):505-512
[21]Yoshitake F, Itoh S, Narita H, et al. Intedeukin-6 direetly inhibits osteoelast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem,2008;283(17):11535-11540
[22]Blanchard F, Duplomb L.Baud'huin M, et al. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev,2009;20(1):19-28.
[23]梁少俊,刘宏,杨力,等.绝经后骨质疏松与血清OPG及RANKL关系的研究.广东医学,2006；27(5)：669-671
[24]Rogers A,Saleh QHannon RA,et al.Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.J Clin Endocrinol Metab,2002;87:4470-4475.
[25]郭梁.成骨细胞、破骨细胞及OPG/RANKL/RANK轴与骨质疏松症.中医正骨,2010；22(7)：41-44
[26]刘建民,赵红燕,宁光,等.20-75岁妇女血清护骨素、核因子κB受体活化子配体的变化与年龄、停经、骨生化指标和骨密度的关系.中华内科杂志,2004；43(6)：447-450
[27]Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab,2001;86:631-637
[28]商敏.OPG/RANKL/RANK系统与绝经后骨质疏松症.中国骨质疏松杂志,2008；14(7)：532-535
[29]贾少杰,贾晓静.雌激素抗骨质疏松的OPG和A poE作用机制的实验研究.中国老年学杂志,2007；27(12)：2274-2276
[30]涂平生,徐杰.护骨素的研究进展.解剖学研究,2004；26(4)：301-304
[31]王晓庚,刘文佳,周洪,等.不同浓度破骨细胞分化因子和巨噬细胞集落刺激因子体外诱导大鼠破骨样细胞形成的研究.口腔医学,2008；28(40)：169-172
[32]杨健,谭颖徽,裘松波.核因子KB受体活化因子配体诱导大鼠骨髓破骨细胞形成的实验研究.重庆医学,2004；33(3)：385-388
[33]Jilka RL.Cytokines,bone remodeling,and estrogen deficiency:a 1998 update.Bone,1998;23(2):75-81
[34]Russel RG,Espina B,Hulley p,rt al.Bone biology and the pathogenesis. Curr-Opin-Rheumatol,2006; 18(Supplel):3-10
[35]Handy N A.Targeting the RANK/RANKL/OPG signaling pathway a novel approach in the management of osteoporosis. Curr Op in Investing Drugs,2007;8(4):299-303